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ABSTRACT 
 
 
Invasive fungal infections are prevalent and often deadly in immunocompromised 
patients.  There continues to be a pressing need for the development of novel antifungal 
compounds since there are currently only 13 compounds licensed for the treatment of 
invasive fungal infections and antibiotic-resistant strains have been emerging.  CAY-1 is 
an antifungal steroidal saponin which was isolated from the fruit of the cayenne pepper 
plant in 0.1% yield.  In Vitro studies of CAY-1 have shown it to be an effective 
antifungal agent against sixteen pathogenic fungal strains and it showed no cytotoxicity 
toward mammalian cells up to 100 µg/mL.  The development of a practical synthesis of 
CAY-1 will potentially allow for further exploration of its medicinal utility and provide 
the opportunity to synthesize derivatives of CAY-1 which could be investigated in 
structure-activity relationship studies.  To this end, methods for the preparation of they 
CAY-1 aglycone and pentasaccharide moieties have been investigated. 
Through this work, several partially protected stereoisomers of the CAY-1 
aglycone have been prepared which can be used for the synthesis of saponin derivatives 
of CAY-1 for structure-activity relationship studies.  Definitive characterization of one of 
these isomers, 3α-hydroxy-(22S,25R)-5α-spirostan-2β-yl acetate, was achieved by X-ray 
crystallography.  Furthermore, a quantitative inversion of the C-3 stereochemical 
configuration of this compound was achieved via an acetate group migration of the 
corresponding mesylate.  The possibility of competition between the acetate migration 
and substitution mechanisms with various nucleophiles was explored.  The results, 
however, indicate that this inversion only occurs via the acetate migration. 
 xiv
Additionally, the CAY-1 pentasaccharide synthesis poses two significant 
challenges.  First, these results demonstrate that the central 2,3-branched portion can be 
synthesized efficiently from a partially protected glucopyranosyl acceptor since the C-2 
and C-3 alcohols differ in their reactivity in glycosylation reactions.  The second 
challenge is the β-(1→4) linkage to the galactosyl acceptor which significantly increases 
the complexity of the synthesis as compared to literature reported syntheses of other 
branched oligosaccharides.  Nonetheless, this β-(1→4) linkage was achieved using a 
disarmed trichloroacetimidate glucosyl donor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: 
Antifungal compound, CAY-1, invasive fungal infections, glycoconjugate, natural 
product synthesis, saponins, spirostane, 2,3-branched oligosaccharide synthesis. 
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INTRODUCTION 
 
Pharmacological Need for Novel Antifungal Compounds 
Pathogenic fungi cause a wide variety of infections in humans and most of these, 
including skin, mucosal, and allergic infections, are not typically life-threatening.  
However, although rare in individuals with healthy immune systems, invasive fungal 
infections, which affect the major internal organ systems of the body, are prevalent and 
often deadly in immunocompromised patients such as bone marrow transplant recipients, 
AIDS patients, and cancer patients receiving antineoplastic chemotherapy.  The most 
important risk factors associated with the development of invasive fungal infections are 
neutropenia, which is characterized by an abnormally low number of neutrophilic 
leukocytes in the blood, exposure to broad-spectrum antibiotics, and exposure to an 
environment with high levels of pathogenic fungi.   
Invasive fungal infections are most commonly caused by members of the genera 
Candida and Aspergillus.  For example, the incidences of invasive Candida and 
Aspergillus infections in bone marrow transplant recipients are 10-15% and 3-7% 
respectively and the attributable mortality rate is 60-95%.1  Overall, Candida infections 
are the fourth most common type of nosocomial bloodstream infection in the United 
States and have a higher mortality rate (33-47%) than any other bloodstream infection.2  
Furthermore, there has been a fourteen fold increase in the frequency of opportunistic 
invasive fungal infections from 1980-1992 in the United States and Europe.3 
This increase in incidence of invasive fungal infections in immunocompromised 
individuals is largely attributed to medical advancements in the treatment of these 
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patients, especially in the management of bacterial infections.  In fact, it has been 
estimated that the development of antibiotics has increased the life expectancy of humans 
by ten years.4  Although physicians have had success in increasing the life expectancy of 
immunocompromised patients by treating bacterial infections, they are now struggling to 
treat the resulting opportunistic invasive fungal infections.  Just as antibiotic resistant 
bacteria appeared soon after the introduction of the first antibiotics, the problem of 
antifungal resistance has been emerging as the use of existing antifungal agents has 
increased in response to increasing incidences of life-threatening fungal infections. 
In order to avert the problem of antimicrobial resistance, the successful 
management of fungal infections requires a large number of antifungal agents belonging 
to a wide variety of classes with different mechanisms of action.  Additionally, the 
patients most at risk for invasive fungal infections are typically taking several 
medications to treat the underlying diseases causing their neutropenia.  Therefore, it is 
also important that physicians have access to a large number of antifungal medications to 
improve their chances of finding one that is both effective for treating the infection and 
will not interact with other medications the patient may be taking.  Unfortunately, there is 
still a dire need for the development of new antifungal compounds.  As of 2000, there 
were only ten medications approved by the U.S. Food and Drug Administration (FDA) 
for use in the treatment of invasive fungal infections and these drugs belong to only three 
classes: polyenes, pyrimidines, and azoles. 
The polyene class includes the classic amphotericin B (1), which was approved by 
the FDA in 1958 but is still considered the “gold standard” for the treatment of invasive 
fungal infections because it has the broadest spectrum of effectiveness.  Polyenes act by 
 3
binding to ergosterol, the primary sterol component in fungal cell membranes, and 
thereby altering the permeability of the cell membrane and causing cell death.  However, 
it is generally not as effective against Aspergillus infections as it is towards other fungal 
genera and its dosage is limited by significant toxicity, especially nephrotoxicity.  From 
1995-1997 the FDA approved three lipid formulations of amphotericin B which are less 
toxic than the original formulation, but they are more expensive and are not more 
effective.5 
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O OH OH
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OH OH
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H3C OH
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HO
H3C
O
COOH
H
O
O CH3OH
NH2
HO
1 (Amphotericin B)   
 
Flucytosine (2) is the only systemic antifungal agent in the pyrimidine class.  It 
was originally synthesized as an anticancer compound but unlike similar compounds in 
this class, it failed to show antineoplastic activity.  Subsequently, its antifungal 
capabilities towards Candida species were discovered and the FDA approved flucytosine 
as a systemic antifungal medication in 1972.  Flucytosine enters fungal cells and disrupts 
DNA synthesis by incorporating itself into the fungal RNA.  Due to its toxicity and the 
appearance of drug resistance in Candida species, flucytosine is primarily only used 
today in combination with amphotericin B to treat Cryptococcus neoformans which is 
one causative agent of meningitis.6 
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Three azoles, ketoconazole (3), fluconazole (4), and itraconazole (5) gained 
widespread use in the treatment of invasive fungal infections in the 1980’s and 1990’s 
due to their broad spectrum of activity and low toxicity.  Azoles act by inhibiting the 
synthesis of ergosterol, thereby resulting in abnormalities in the fungal cell membranes.  
While drug resistance has emerged in Candida species, the major limitation in the use of 
azoles has been problems with widespread drug interactions.7  Even so, azoles remain as 
important systemic antifungal agents and recent research has led to the development and 
FDA approval of voriconazole (6) in 2002 which has proven to be a highly effective 
broad spectrum treatment for invasive fungal infections and is less toxic than 
amphotericin B.  Indeed, one study has shown voriconazole to be a better choice over 
amphotericin B for the prevention of fungal infections in immunocompromised patients.8 
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A fifth azole, posaconazole (7), gained FDA approval in 2006 for the prevention 
of invasive fungal infections caused by Candida and Aspergillus species.  Like the other 
azoles, posaconazole acts by inhibiting the synthesis of ergosterol but it appears to be a 
more potent inhibitor of sterol biosynthesis than other azoles especially in the Aspergillus 
species.  Recent clinical trials have shown posaconazole to be more effective than 
fluconazole or itraconazole in the prevention of invasive fungal infections in 
immunosuppressed patients.  Additionally, it was shown to be effective against systemic 
fungal infections that did not respond to treatment with amphotericin B.  However, 
posaconazole also appears to be more hepatotoxic than fluconazole and itraconazole.9 
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The FDA approval of caspofungin acetate (8) in 2001 brought, for the first time in 
fifteen years, an antifungal compound to the market that belongs to a new class, 
echinocandins.  These compounds disrupt the synthesis of β-(1,3)-D-glucan, a vital 
component of Candida and Aspergillus fungal cell membranes.  This mechanism of 
action limits the effectiveness of echinocandins to infections caused by these genres, but 
the majority of invasive fungal infections do result from Candida and Aspergillus 
species.10  A second echinocandin, anidulafungin (9), gained FDA approval in 2006 and 
has been shown in clinical trials to be more effective than fluconazole in the treatment of 
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invasive candidiasis.11  Anidulafungin shows low toxicity and, unlike azoles, has not 
shown significant adverse drug-drug interactions.12 
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Even with these recent advances, there are currently only thirteen medications 
approved by the FDA for the treatment of invasive fungal infections and they belong to 
only four different classes of compounds.  Additionally, of these thirteen medications, 
four of them are lipid formulations of the same compound, amphotericin B.  In contrast, 
even the hundreds of antibacterial medications on the market which mostly belong to 
eight classes are deemed insufficient due to the rapid emergence of antibiotic resistant 
bacteria.  Therefore, there continues to be a pressing need for the development of novel 
antifungal compounds. 
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Natural Products Drug Discovery 
Recently there has been a renewed interest in research on natural products as 
leads and targets for drug discovery.  In fact, they have been the traditional source for 
medicines since the times of ancient civilizations, and even today half of the drugs on the 
market are either natural products or were inspired by them.  Despite this record of 
success, American pharmaceutical companies largely abandoned natural product research 
in favor of combinatorial chemistry in the 1980’s and 1990’s in an effort to reduce the 
amount of time and money required for drug development.  The development of high-
throughput screening allowed for the automated testing of thousands of compounds for 
biological activity per day.  While traditional stepwise organic synthesis could not meet 
the demand for new compounds, combinatorial chemistry increased the productivity of 
synthesis labs from one or two hundred new compounds per year to tens of thousands. 
Unfortunately, these modern drug discovery techniques have failed to identify 
large numbers of ultimately successful leads.  Whereas combinatorial chemistry alone has 
only provided a few candidates that have reached clinical trials, 61% of the new small-
molecule drugs introduced from 1981-2002, and 23 of the compounds that gained FDA 
approval from 2000-2005, originated from natural product chemistry.  Natural products 
are even more promising in the identification of new antibiotic agents.  For example, 79% 
of the antibacterial compounds that were introduced from 1982-2002 were inspired by 
natural products.13,14   
Additionally, while pharmaceutical companies emphasized the use of high-
throughput screening for drug discovery, at the same time there has also been trend from 
1996-2006 toward a decrease in the total number of new molecular entities approved by 
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the FDA.15  However, in the future, as advances in combinatorial chemistry are making it 
possible to synthesize libraries of compounds that are increasingly complex, the 
combination of natural product and combinatorial chemistry promises to provide a 
powerful research and development tool for the pharmaceutical industry. 
Saponins 
One family of natural product compounds that shows promise in the identification 
of novel antifungal compounds is the saponin family.  Saponins are divided based on the 
structure of their aglycone moiety into three classes: the steroid class, the triterpene class, 
and the steroid alkaloid class (Figure 1).  In addition, saponins have an oligosaccharide 
moiety of up to five sugar molecules usually attached to the C-3 position of the aglycone 
and some saponins also have a C-26 or C-28 sugar moiety.  The oligosaccharide typically 
consists of a combination of glucose, arabinose, glucuronic acid, rhamnose, or xylose.16 
 
Figure 1.  Classes of saponins. 
O
O
HO
3
26
Steroid class
O
H
N
HO
3
26
Steroid alkaloid class
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3
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H
H
H
H
 
 
Saponins are named after one of their most notable characteristics, their 
amphiphilicity due to the lipophilic steroidal or triterpene moiety and the hydrophilic 
oligosaccharide moiety. 17  Many plants produce saponins as secondary metabolites that 
primarily serve as antimicrobial agents and traditionally it was believed that plants were 
the only natural source of saponins.  More recently, however, biologists have discovered 
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that saponins are also abundant in many marine animals, most notably in echinoderms, 
but they also appear occasionally in higher animals such as fish.18 
Medicinally, saponins have a wide range of biological activity that goes beyond 
their antimicrobial roles to include hypocholesterolemic, anti-inflammatory, anti-diabetic, 
anti-allergenic, immunomodulatory, anti-hepatotoxic, and anti-cancer capabilities.19  It 
has been shown that both the aglycone and oligosaccharide moieties of saponins are 
important for their biological activity.20-24  While the effectiveness of saponins has been 
recognized for centuries in herbal medicine, they were not typically viewed as potential 
drug targets in the past due to their structural complexity.  One exception is digoxin (10), 
a cardiac glycoside that has been isolated from the leaves of the foxglove plant Digitalis 
lanata and marketed for over 200 years to treat congestive heart failure.  Digoxin binds to 
Na+/K+ ATPase pumps in cardiac cell membranes.  This alters the membrane potential by 
changing the concentrations of ions and ultimately leads to an increase in the strength of 
the contraction of the cardiac muscles.19   
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Unfortunately, digoxin is an unusual saponin in its availability by isolation from 
natural sources in sufficient quantities for distribution.  Even so, recent advances in the 
synthesis of glycoconjugates allowed further exploration of additional medicinal uses for 
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saponins.  In fact, saponins have drawn much attention in recent years owing in large part 
to OSW-1 (11), a steroidal saponin isolated from bulbs of the lily plant Ornithogalum 
saudersiae.  OSW-1 shows in vitro anti-tumor activity levels that are 10-100 times more 
effective than many well-known anticancer compounds including taxol and cisplatin.25  
Furthermore, this saponin has the potential to be effective against cancers that are 
resistant to currently available chemotherapy because it has an unusual mechanism of 
action.  Upon entering a cancer cell, OSW-1 causes damage to the mitochondrial 
membranes, which in turn disrupts the calcium levels in the cytoplasm of the cell and 
ultimately causes cell death by apoptosis.26 
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Many saponins have also been well documented to possess potent in vitro 
antifungal properties.  For example, saponin 12 is a derivative of the triterpene 
medicagenic acid which was isolated from alfalfa root extracts.  Initial testing revealed 
that 12 was effective against fungal skin infections in guinea pigs and did not show 
dermal toxicity in rhesus monkeys.  It also showed promise toward the treatment of 
invasive fungal infections by successfully curing Cryptococcus neoformans infections in 
mice with a minimal fungal concentration of 4 µg/mL.  Saponin 12 was also effective 
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against amphotericin B-resistant strains of Candida tropicalis.  It was synthesized in 
three steps from medicagenic acid and acetobromomaltose in 49% overall yield.27 
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Isolation and Characterization of CAY-1 
CAY-1 (13) is an important newly identified saponin that has the potential to be 
useful in the treatment of invasive fungal infections.  It was isolated in 0.1 % yield from 
the fruit of the cayenne pepper plant Capsicum frutescens (Scheme 1).  Each fraction 
obtained from the solid phase extraction stage of the isolation procedure was tested for 
fungicidal activity.  CAY-1 is not detectable by UV so its presence was determined by 
mass spectrometry and bioassays.  Activity was found only in the 75% methanol fraction 
which was then finally purified by high-pressure liquid chromatography (HPLC).  The 
structure of CAY-1 was determined by nuclear magnetic resonance including total 
correlation spectroscopy (TOCSY), heteronuclear multiple-quantum coherence (HMQC), 
and heteronuclear multiple-bond correlation (HMBC).28 
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Scheme 1.  Isolation of CAY-1. 
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Biological Activity of CAY-1 
 Sufficient quantities of CAY-1 were available by isolation from cayenne peppers 
to perform preliminary testing for antifungal activity and cytotoxicity toward mammalian 
cells.  It was shown to be an effective antifungal agent against sixteen fungal strains of 
Candida species, Aspergillus fumigatus, Cryptococcus neoformans, and Neurospora 
crassa (Table 1).  All of these strains are human pathogens known to cause invasive 
fungal infections in immunocompromised patients.  The most promising result was the 
activity of CAY-1 against C. neoformans (IC90 = 1µg/mL) which causes cryptococcal 
meningitis, a fatal disease if left untreated.28,29 
 
Table 1.  CAY-1 whole cell activity.28 
Microorganism American Type Culture Collection no. 
Inoculum 
(cells mL-1) 
IC90 
(µg/mL) 
IC50 
(µg/mL) 
Candida albicans 90028 1 x 104 8-16 8-16 
 10231 1 x 105 31 16 
 44203 1 x 104 4-8 4-8 
 32354 1 x 105 16 8 
 44806 1 x 105 8-16 8-16 
 76485 1 x 105 16 16 
 90234 1 x 104 16 8 
 #5 (not an ATCC strain) 1 x 104 16 8 
 90873 1 x 105 8-16 8-16 
C. glabrata 48435 5 x 104 8-16 4 
C. tropicalis 90874 1 x 105 63 32 
C. krusei 34135 1 x 105 > 125 32 
C. parapsilosis 90018 1 x 105 16 8 
Aspergillus fumigatus 16424 1 x 105 31 16 
Cryptococcus neoformans 36556 5 x 105 1 1 
Neurospora crassa (not an ATCC strain) 1 x 105 4 4 
 
 
 CAY-1 was also tested for synergistic activity with three known antifungal 
agents, amphotericin B, miconazole, and cilofungin against C. albicans and A. fumigatus.  
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Drug synergism reduces the inhibitory concentration of the drugs and is therefore 
especially important for compounds that have toxic side effects at higher concentrations.  
In order to determine if two compounds are synergistic, the combined fractional 
inhibitory concentration (FIC) for each is calculated by dividing the minimal inhibitory 
concentration (MIC) of the drug in combination by the MIC of the drug alone.  If the sum 
of the FIC’s for the two drugs is less than 0.5, the compounds are considered synergistic.  
Using this methodology, it was determined that CAY-1 acts synergistically with 
amphotericin B against both C. albicans and A. fumigatus, a promising result considering 
the known toxicity of amphotericin B.29,30 
 Finally, CAY-1 was tested in vitro for cytotoxicity against 55 mammalian cell 
lines.  The cells tested showed no inhibition of growth upon exposure to up to 100 µg/mL 
of CAY-1.24  Further testing is needed, however, to determine the lethal dose for CAY-1 
and to obtain in vivo results for cytotoxicity against mammalian and fungal cells. 
CAY-1 Mechanism of Action 
 It is known that saponins alter the permeability of fungal cell membranes, which 
allows intracellular components to leak out of the cell and ultimately causes cell death.  
This was demonstrated with CAY-1 by treating N. crassa spores with [14C]-alpha-amino-
isobutyric acid.  The radioactivity remaining in the cells after treatment with 25 µg/mL of 
CAY-1 was measured using a liquid scintillation counter and compared to controls which 
were dosed with dimethylsulfoxide (DMSO).  The results show that the radioactivity in 
the treated cells decreased significantly after five minutes, suggesting that the integrity of 
the cellular membranes had been compromised (Figure 2). 
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Figure 2.  The effect of CAY-1 (20 µM) compared to DMSO controls on fungal cell 
permeability.29 
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The exact mechanism by which saponins alter the permeability of fungal cell 
membranes is not clear.  The tendency of saponins to bind to steroids suggests that 
antifungal saponins which are not toxic toward mammalian cells may bind preferentially 
to ergosterol, the major sterol component in fungal cell membranes, rather than 
cholesterol, the major sterol component in mammalian cell membranes.  Once bound, the 
sterol-saponin complexes may aggregate to create pores in the membrane or to extract the 
sterol components from the membrane (Figure 3).  Evidence to support the formation of 
pores in fungal membranes upon exposure to saponins has been provided by electron 
microscopic analysis.16 
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Figure 3.  Cell membrane disruption by saponins.16 
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Specific Aims for the Synthesis of CAY-1 
 The rationale for the research towards the synthesis of CAY-1 is threefold.  First, 
due to the difficulty in characterizing the structure of saponins isolated from nature,31,32 
the synthesis of this compound will provide verification for the precise structure and 
stereochemistry of this complex glycoconjugate.  Of particular concern is the 
stereochemistry of the five glycosidic bonds contained in the CAY-1 structure.   
Second, the development of a practical synthesis of CAY-1 will potentially 
provide a sample that is of sufficient quantity and purity to further explore its biological 
activity and medicinal utility as well as its mechanism of action.  While the 0.1% isolated 
yield from the Capsicum frutescens plant is not exceptionally low, the laborious isolation 
process has limited the availability of CAY-1 in sufficient quantity and purity for 
additional biological testing.  Consequently, the biological results obtained thus far are 
severely limited in their ability to predict the utility of CAY-1 in the treatment of invasive 
fungal infections.   
Finally, a practical synthetic strategy would also allow for the opportunity to 
synthesize derivatives of CAY-1 which could be investigated in the future in structure-
activity relationship studies.  Since CAY-1 is only one of many biologically active 
saponins contained in the epithelial cells of the Capsicum frutescens plant, it is likely that 
the synthesis of structurally similar saponins will yield other biologically active 
compounds. 
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RESULTS AND DISCUSSION 
CAY-1 AGLYCONE MOIETY 
 
Retrosynthetic Analysis of CAY-1 
 The structure of CAY-1 consists of a sterol aglycone moiety and a 
pentasaccharide moiety attached to the C-3 position of the aglycone.  Due to the 
complexity of each moiety, the most efficient approach to the synthesis of CAY-1 was 
deemed to be a convergent synthesis in which aglycone 14 and pentasaccharide 15 are 
synthesized separately and then joined via a glycosidic bond in the penultimate stage of 
the project.   
The retrosynthesis of CAY-1 (Scheme 2) illustrates how hecogenin acetate (16) 
could be used as the starting material for the aglycone.  This would require two synthetic 
transformations.  First, the C-12 ketone would need to be reduced to a methylene to form 
tigogenin (17).  The second transformation, the addition of an α-hydroxy substituent at C-
2, would be significantly more complicated.  Not only is the conversion of an alcohol into 
a trans-1,2-diol not straightforward for steroids, in this case it is also necessary to protect 
the C-2 alcohol in preparation for the reaction of the C-3 alcohol with the pentasaccharide 
moiety. 
Additionally, the pentasaccharide would be synthesized by the appropriate 
assembly of four glucose units and one galactose unit.  The challenge for the synthesis of 
this moiety stems from the inclusion of a 2,3-branched glucose unit.  The galactose unit 
also complicates the synthesis since the required β-(1→4) linkage between the 2,3-
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branched glucosyl donor and the galactosyl acceptor is disfavored as compared to an α-
(1→4) linkage. 
 
Scheme 2.a  Retrosynthesis of CAY-1. 
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aR = appropriate alcohol protecting groups.  L = appropriate leaving groups for glycosidic bond formation. 
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 Overall, there are several key challenges to the preparation of CAY-1.  The first is 
the transformation of the 3β alcohol of hecogenin acetate into the corresponding 
spirostane-2α,3β-diol.  Furthermore, since these are both equatorial alcohols, it is crucial 
for them to be differentiated by protecting groups in order for the aglycone to be useful in 
subsequent glycosylation reactions.  Even more complex is the synthesis of the CAY-1 
pentasaccharide owing to its 2,3-branched glucose unit which is bound to the C-4 alcohol 
of the galactose unit by a β-glycosidic bond.  The development of practical methods for 
the accomplishment of these synthetic transformations will make it possible not only to 
synthesize CAY-1 but also saponin derivatives that could be tested for biological activity. 
Initial Retrosynthetic Analysis of the CAY-1 Aglycone 
 The non-protected CAY-1 aglycone (14, R = H) is a known compound derived 
from the hydrolysis of the saponin gitonin (18).  This saponin is one of the minor saponin 
components obtained during the isolation of the saponin digitonin (19) from Digitalis 
purpurea.33  Digitonin is a toxic saponin which precipitates cholesterol and is therefore 
useful in the permeabilization of cellular and nuclear membranes.   
While this saponin mixture is commercially available from a number of sources, it 
is impractical as a starting material for the preparation of CAY-1.  This is due to the fact 
that gitonin is only a minor component of the commercially available digitonin mixture.  
Consequently, obtaining 14 from commercial sources would require separation of a 
minor saponin component from a saponin mixture followed by hydrolysis of the saponin 
to obtain non-protected aglycone component 14.  Furthermore, selective protection and 
isolation of one of two neighboring equatorial secondary alcohols would need to be 
accomplished before a glycosylation with an oligosaccharide moiety could be performed. 
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Therefore, a strategy for the synthesis of aglycone 14 from more abundant sterols 
was investigated.  A literature search revealed a synthesis by Sondheimer et al. of the 
CAY-1 aglycone in 5 steps from diosgenin (Scheme 3).33-35  In this synthesis, diosgenin 
(20) was oxidized to α,β-unsaturated ketone 21 by an Oppenauer oxidation which was 
then subjected to an allylic bromination to give 22.  The key step in this approach, 
involving an acetolysis of 22 to form α-acetoxy ketone 23, proceeded in only 25% yield, 
severely limiting the usefulness of this strategy in a more complicated synthesis.  To 
complete the synthesis, hydrogenation of the alkenyl functionality of 23 was followed by 
reduction of both the C-2 acetate protecting group and the C-3 ketone of 24 by LiAlH4 to 
give unprotected trans-1,2 diol 25 in 5% overall yield from diosgenin. 
There were two concerns about the utility of this synthesis for the preparation of 
CAY-1.  The first concern was the low yield since aglycone 14 would be an intermediate 
in the saponin synthesis.  More importantly, the lack of a protecting group on either the 
C-2 or C-3 alcohol in 24 renders it unusable in a glycoconjugate preparation.  Since both 
of these secondary alcohols are equatorial, it would not be feasible to selectively protect 
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one over the other.  The development of a new synthetic strategy was therefore 
considered necessary in the hopes of discovering a practical synthesis of CAY-1. 
 
Scheme 3.  Literature reported synthesis of CAY-1 aglycone by Herran et al.33-35 
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 The synthesis of the steroid moiety of CAY-1 (14) from commercially available 
hecogenin acetate (16) was originally planned utilizing a partially protected trans-1,2 diol 
formation via an epoxide ring opening of 26β with acetic acid.  The epoxide could be 
formed from spirost-2-ene (27) which would be synthesized from tigogenin (18) by the 
elimination of the C-3 xanthate esters 28 or 29.  Tigogenin (18), in turn, would be 
available from hecogenin acetate (16) by the reduction of the C-12 ketone to a methylene 
(Scheme 4).  Tigogenin is also commercially available although it is considerably more 
expensive than hecogenin acetate and so it was not chosen as the starting material for this 
synthesis. 
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Scheme 4.  Initial retrosynthesis of the CAY-1 aglycone. 
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First Attempt to Synthesize the CAY-1 Aglycone 
 Spirost-2-ene (27) was prepared from commercially available hecogenin acetate 
(16) in 87% yield over three steps following literature procedures with minor 
modifications (Scheme 5).36-38  In the first step, hecogenin acetate was reduced to 
tigogenin (17) by a Huang-Minlon modified Wolff-Kishner reduction.  The C-3 alcohol 
was simultaneously deprotected in these reaction conditions.  The C-3 alcohol of 17 was 
then converted to its propargyl xanthate ester (28) which rearranged to form spirost-2-ene 
in refluxing toluene with a collidinium trifluoromethanesulfonate catalyst.  Alternatively, 
27 was prepared by a Chugaev elimination via the pyrolysis of methyl xanthate ester 
29.39-41 
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Scheme 5.a  Synthesis of spirost-2-ene from hecogenin acetate. 
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aReaction conditions: (a) Hydrazine hydrate, 2-ethoxyethanol, KOH, 136°C, 98%.  (b) NaH, CS2, propargyl 
bromide, THF.  (c) NaH, CS2, CH3I, THF.  (d) Collidinium trifluoromethanesulfonate (0.1 eq.), toluene, 
reflux, 89% (2 steps from 17).  (e) 200°C, 94% (2 steps from 17). 
 
 
The difference in temperature requirements for these two eliminations can be 
explained by their mechanisms (Scheme 6).  In the elimination of the propargyl xanthate 
ester, the collidinium trifluoromethanesulfonate salt catalyzes the rearrangement so that it 
proceeds at lower temperatures (110°C vs. 200°C).  Without the catalyst, the elimination 
proceeds by the same mechanism as the methyl xanthate ester, known as the Chugaev 
reaction, and requires the same high temperature.  Because of the thermal stability of this 
steroid, there was essentially no real advantage of one elimination method over the other 
since both provide spirost-2-ene in similar yield (89% for propargyl xanthate 28 and 94% 
for methyl xanthate 29). 
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Scheme 6.  Mechanisms for the elimination of xanthate esters to spirost-2-ene.37,41 
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Epoxidation of 27 with m-CPBA proceeded in 94% yield.  Unfortunately, the 
comparison of the 1H NMR spectra of the major (91%) and minor (3%) isomers obtained 
in this reaction revealed that the 2α,3α-epoxide 26 was the major product.  Most notably, 
the chemical shift for the C-19 methyl group for 26α was 0.75 ppm as compared to 1.04 
ppm for 26β (Figure 4).  The downfield shift for this signal in the case of 26β is due to 
the fact that the methyl group is on the same side of the molecule as the epoxide in this 
isomer.  This result is reasonable since epoxidations with m-CPBA generally occur from 
the least hindered side of the alkene.42,43  In this case, the C-19 methyl renders the β-face 
of the molecule more hindered than the α-face and thus the α-epoxide is the major 
product (Scheme 7).  Note that β-epoxidation does occur but only 3% of this product was 
obtained due to steric hinderance. 
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Figure 4.  Comparison of 1H NMR spectra (400 MHz, CDCl3) for 26α and β. 
 
 
 
Scheme 7.  Epoxidation of spirost-2-ene (27) with m-CPBA. 
 
CH3
Cl
O
O
O
H
H
Top face of steroid sterically hindered by
C-19 methyl group so epoxidation occurs 
from    -face nearly exclusively
CH3
HO
Major (91%)
CH3
H
O
Minor (3%)
+
CH3
CH3 CH3
26α 26β
α
27
 
HO
CH3
26α
CH3
CH3
H
O
CH3
26β
C-19 CH3
C-19 CH3
 27
Hoping to still be able to synthesize the desired steroid via an epoxidation route, 
reagents favoring the 26β product were investigated.  The epoxidation of the more 
sterically hindered side of cholesterol 3-benzoate (30) and 3β-acetoxyprogest-5-en-20-
one (31) to their 5β,6β-epoxides were successful in the literature using KMnO4-CuSO4.44  
However, attempts to apply these reaction conditions to spirost-2-ene (27) were 
unsuccessful. 
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 Next, the epoxide ring opening of 26α and 26β was explored.  In both cases the 
acetic acid nucleophile approaches each epoxide axially to give the diaxial isomers 32 
and 33 in 84% and 71% yield respectively (Scheme 8).  This result is supported by the 
fact that in ring systems, nucleophilic attack on epoxides generally occurs from an axial 
approach.45,46  Additionally, the appearance of H-2 and H-3 as broad singlets in the 1H 
NMR of 3α-hydroxy-spirostan-2β-yl acetate (32) confirms their equatorial orientation 
(Figure 5).  Axial protons, as in H-3 of tigogenin (17) which is also shown in Figure 5 for 
comparison, appear as multiplets.  This is due to the difference in the coupling constants 
between equatorial and axial protons.  The stereochemistry of 32 was further confirmed 
by X-ray crystallography (Figure 6).  Therefore, further attempts to synthesize 26β in 
good yield were abandoned considering the fact that either epoxide leads to a diaxial 
trans-1,2 diol derivative upon reaction with acetic acid. 
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Figure 5.  Portion of 1H NMR (400 MHz, CDCl3) of 3α-hydroxyspirostan-2β-yl acetate 
(25) and tigogenin (18) showing C-2 and C-3 stereochemistry. 
 
 
 
 
Figure 6.  ORTEP drawing of 3α-hydroxyspirostan-2β-yl acetate (32).  (Courtesy of E. 
D. Stevens, University of New Orleans) 
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Scheme 8.  Epoxide ring opening of 26α and β with acetic acid. 
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Second Retrosynthetic Analysis of the CAY-1 Aglycone 
 Holzapfel et al. reported the synthesis of a glycoconjugate containing the same 
steroid moiety as CAY-1 (Scheme 9).  Their synthesis began with diosgenin (20) which 
provided tigogenin (17) by catalytic hydrogenation.  Next, tigogenin was oxidized using 
chromic acid to spirostan-3-one (34) which was then converted to trimethylsilyl enol 
ether 35.  Enol ether 35 was oxidized with dimethyldioxirane (DMDO) and the resulting 
α-hydroxy ketone was protected as allyl carbonate 36.  To this point, each step in this 
literature report was accomplished in high yields of no less than 83%.  Unfortunately, the 
last step, requiring a stereoselective reduction of the C-3 ketone of 36 to the β-alcohol 
using sodium borohydride, provided the desired stereoisomer 37 in only 63% yield.47 
Successful syntheses of trans-1,2 diols from trimethylsilyl enol ethers using 
hydroboration-oxidation has been reported for substituted cyclohexenol derivatives.48  
Therefore, a new retrosynthesis (Scheme 10) for the steroid moiety of CAY-1 was 
designed using the trimethylsilyl enol ether intermediate 35 described in the synthesis by 
Holzapfel et al.  Although the reported yields for the hydroboration-oxidation of 
trimethylsilyl enol ethers are low (~60%), this method would still provide the opportunity 
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for a higher yielding synthesis since it would require fewer steps.  In this proposed 
synthesis, the aglycone would be prepared by the hydroboration-oxidation of 
trimethylsilyl enol ether 35 to give selectively protected diol 38.  This silyl enol ether 35 
would be synthesized from spirostan-3-one 35 which is available from the oxidation of 
tigogenin (17). 
 
Scheme 9.  Literature reported synthesis of CAY-1 aglycone by Holzapfel et al.47 
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Scheme 10.  Retrosynthesis of the CAY-1 aglycone via TMS enol ether intermediate 35. 
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Second Attempt to Synthesize the CAY-1 Aglycone 
 Tigogenin (17), which had been prepared as described above from hecogenin 
acetate (16), was successfully oxidized with chromic acid to spirostan-3-one (34) in 93% 
yield (Scheme 11).  Since the desired 2,3-enolate of 34 is both the kinetically and 
thermodynamically favored product, trimethylsilyl enol ether 35 was prepared from 
ketone 34 in good yield (76%) using lithium diisopropylamide and trimethylsilyl 
chloride.  This is due to the fact that the AB ring junction of the steroid not only creates 
steric hinderance but it is also has increased rigidity and therefore the resulting sp2 
carbons are more strained the closer they are to a ring junction.   
Unfortunately, the hydroboration-oxidation of enol 35 using 9-BBN did not 
provide the desired trans-1,2 diol.  Instead, this reaction resulted in a mixture of products 
mostly consisting of 2α-hydroxyspirostan-3-one (39) and spirostan-3-one (34).  This 
suggests that under these reaction conditions 9-BBN did not react with trimethylsilyl enol 
ether 35.  Therefore, once the solution of sodium hydroxide and hydrogen peroxide were 
added to the reaction mixture, 35 was still present to be oxidized to α-hydroxy ketone 39.  
Since hydrogen peroxide does not generally oxidize alkenes in high yield, it is not 
surprising that the other major product formed in this step was the regeneration of ketone 
34, presumably from the deprotection of remaining 35 during the acidic work-up. 
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Scheme 11.a  Attempted synthesis of the CAY-1 aglycone via TMS enol ether 35. 
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aReaction conditions: (a) H2CrO4, acetone, 30°C, 93%.  (b) LDA, TMSCl, DME, 0°C, 76%.  (c) 1. 9-BBN, 
2. H2O2, NaOH. 
 
 
Third Attempt to Synthesize the CAY-1 Aglycone 
 The third approach toward the development of a novel synthesis of the CAY-1 
aglycone involved the inversion of the C-2 and C-3 alcohols of 3α-hydroxy-spirostan-2β-
yl acetate (32).  This would require inversion of the C-3 alcohol, followed by protection 
of this alcohol as a benzyl ether and deprotection of the C-2 alcohol to give 40.  The C-2 
alcohol of 40 would be inverted and then protected again as an acetate ester.  Finally, the 
deprotection of the C-3 benzyl ether would provide the target sterol 14 (Scheme 12).  
These inversions were originally envisioned utilizing an SN2 reaction for the inversion of 
C-3 followed by the inversion of C-2 using Mitsunobu methodology.   
Although this design is less straightforward than the synthesis reported by 
Holzapfel et al., there remains the potential for the improvement in the overall yield of 
the synthesis.  Furthermore, this route is attractive in that it provides stereoisomers of the 
CAY-1 aglycone that could be used in the future for the preparation of saponin 
derivatives of CAY-1 for structure-activity relationship studies.  Such studies could not 
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only optimize its biological activity as an antifungal agent, but they could also help 
elucidate its mechanism of action. 
 
Scheme 12.  Retrosynthesis of CAY-1 aglycone by the inversion of C-2 and C-3 of 32. 
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 This synthesis was inspired by the literature reporting of the inversion of 
secondary alcohols via an SN2 attack on the sulfonate ester of the alcohol by the nitrate 
ion.  The resulting nitrate was then reduced by zinc to reform the alcohol with an overall 
inversion of the stereochemical configuration (Scheme 13).49,50   
 
Scheme 13.  Literature reported inversion of 2° alcohols with NO3-.49.50 
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In the first step, the C-3 alcohol of spirostane 32 was converted to its mesylate in 
83% yield.  Unfortunately, reacting mesylate 41 with tetrabutylammonium nitrate in 
refluxing toluene did not afford the expected nitrate product.  This was discovered when 
zinc failed to react with the product of this nitration reaction.  Instead, IR spectroscopy 
revealed that the functional groups present were an ester and an alcohol.  After flash 
column chromatography, it was determined by 1H NMR that the two constitutional 
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isomers 42 and 43 were formed, each consisting in part of β-substituted carbons at 
positions 2 and 3 (Scheme 14). 
 
Scheme 14.a  Attempt to invert C-3 mesylate of 32 by an SN2 reaction with NO3-. 
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aReaction conditions: (a) MsCl, Et3N, CH2Cl2, 0°C, 83%.  (b) N(C4H9)4NO3, toluene, reflux, 98%. 
 
 At this point, it was not clear whether spirostanes 42 and 43 were formed by the 
C-2 acetate migration of mesylate 41, by the nucleophilic attack of ambient water on the 
C-3 mesylate of 41, or by both of these mechanisms.  To explore this, the reaction was 
repeated in a variety of solvent systems and temperatures (Table 2).  The most practical 
result was obtained when 41 was refluxed in a mixture of pyridine and water.  This 
provided a complete conversion to 42 and 43 in 7 hours as compared to over 48 hours 
required for toluene in the absence of tetrabutylammonium nitrate.  When the reaction 
was attempted in acetone, only 20% conversion was achieved after 24 hours due to the 
lower refluxing temperature of acetone as compared to pyridine.   
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Table 2.  Inversion of the C-3 mesylate of 41 to form 42 and 43. 
Solvent(s) Temperature Time (hours) % Conversiona %42a %43a 
Toluene (with 
N(C4H9)4NO3) 
110°C 2 20 10 90 
Toluene (with 
N(C4H9)4NO3) 
110°C 20 100 40 60 
Toluene (without 
N(C4H9)4NO3) 
100°C 48 70 50 50 
Toluene, H2O 100°C 48 80 50 50 
Acetone, H2O 56°C 24 20 10 90 
Pyridine, H2O 100°C 7 100 10 90 
aYields determined by 1H NMR. 
 
While neither 42 nor 43 was prepared in greater than 80% excess, this was still a 
fortuitous result since overall the stereochemical configuration of C-3 of mesylate 41 was 
inverted in quantitative yield.  Furthermore, 42 and 43 could be easily separated by 
column chromatography since the axially oriented alcohol of 42 created a sufficient 
difference in polarity over the equatorial alcohol of 43.  
Next, the acetate group migration of 3-O-acetyl-2β,3β-spirostanediol (42) was 
explored (Scheme 15).  Although 42 was successfully converted to mesylate 44, refluxing 
44 in a mixture of water and pyridine afforded no inversion of its C-2 configuration.  
Instead, 44 was converted under these conditions back to a mixture of 42 and 43.  
Additionally, this reaction was significantly more sluggish than the comparable reaction 
of mesylate 44, requiring 12 hours for 90% conversion as compared to a quantitative 
conversion for 41 after 7 hours.  In this way, it was determined that 42 and 43 form from 
mesylates 41 and 44 solely by an acetate group migration and not by a substitution 
reaction with water.  Furthermore, since the acetate and mesylate of 44 are both on the β-
face of the steroid, the acetate group migration in this case must occur via an SN1-type 
mechanism.   
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Scheme 15.a  Acetate group migration of 42. 
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aReaction conditions: (a) MsCl, Et3N, CH2Cl2, 0°C.  (b) 1:4 H2O: pyridine, reflux, 73% (two steps). 
 
This is a reasonable explanation for the fact that this mesylate is less reactive 
under these conditions than 41 which is capable of reacting in an SN2 fashion.  It was 
surprising but crucial to determine that mesylate 44 was reacting only by an SN1 
mechanism to form the acetate group migration products, and that no SN2 product 
formation was observed.  Consequently, it was clear that an SN2 reaction at C-2 was 
disfavored as long as there was an acetate group present at C-3. 
Fourth Attempted Synthesis of the CAY-1 Aglycone 
 Based on the success in inverting the stereochemical configuration of the C-3 
alcohol of 32 via an acetate group migration and the inability to invert the configuration 
at carbon 2 while the C-3 alcohol was protected as an acetate ester, a new retrosynthetic 
analysis was designed (Scheme 16).  In this approach, the C-2 alcohol of 46 would be 
inverted by an SN2 reaction with mesylate 45.  Sterol 46 would be prepared by the 
protection of the C-3 alcohol of 43 with a protecting group incapable of migration such as 
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a benzyl ether to give 47 which would be followed by the deprotection of the C-2 
alcohol. 
 
Scheme 16.  Fourth retrosynthesis of the CAY-1 aglycone. 
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 To begin this synthesis, 3β-hydroxyspirostan-2β-yl acetate (43) was prepared as 
described above from hecogenin acetate (16).  The C-3 alcohol was then protected as 
benzyl ether 47, the acetate of which was deprotected to give 3β-benzyloxyspirostan-2β-
ol (46) in 75% yield for these two steps.  46 was then successfully converted to its 
mesylate in 81% yield.  Next, mesylate 45 was refluxed in a 1:4 mixture of water and 
pyridine.  These reaction conditions had seemed promising since unlike the acetate group, 
the neighboring benzyl ether does not migrate.  However, none of the expected SN2 
product 48 was observed.  Instead, 46 was regenerated in 90% yield (Scheme 17). 
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Scheme 17.a  Fourth attempted synthesis of the CAY-1 aglycone. 
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aReaction conditions: (a) Benzyl trichloroacetimidate, CF3SO3H, dioxane, 78%.  (b) NaOH, MeOH, reflux, 
96%.  (c) MsCl, Et3N, CH2Cl2, 0°C, 81%.  (b) 1:4 H2O: pyridine, reflux, 90%. 
 
 
 Due to the literature report of successful inversions of secondary alcohols by the 
reaction of corresponding mesylates with cesium acetate,51 the inversion of mesylate 45 
was attempted using tetrabutylammonium acetate in refluxing toluene.  Unfortunately, no 
substitution occurred under these conditions.  Therefore, since the benzyl ether protecting 
group is stable in basic conditions, mesylate 45 was refluxed with sodium hydroxide in 
DMF in an attempt to favor an SN2 mechanism.  As was the case with water/pyridine, the 
only product observed was the SN1 product, 46.  Considering the fact that in all 
substitution reactions attempted with mesylates 41, 44, and 45 the nucleophiles only 
approached from an axial orientation, even if this required following an SN1 rather than 
SN2 mechanism, it was determined that further attempts to invert the configuration of the 
C-2 alcohol by a substitution reaction would most likely be unsuccessful.   
It should be noted that elimination was not observed for these reactions.  
Substitution is most likely favored over elimination in these cases because the rigidity of 
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the fused ring system limits the ability for the strain on would-be alkenyl sp2 carbon 
atoms to be alleviated. 
Fifth Attempted Synthesis of the CAY-1 Aglycone 
 As an alternative to attempting to invert the C-2 stereochemistry by an SN2 
reaction, the inversion by oxidation of the β-C2 alcohol to a ketone followed by reduction 
to the α-alcohol was explored.  As described above, Holzapfel et al. were only able to 
achieve a 63% yield of the desired stereoisomer using sodium borohydride as the 
reducing agent.  Therefore, it was considered that there was an opportunity to improve on 
this synthetic strategy.  For this strategy, the target sterol would be prepared, after a 
transfer of protecting groups of 50 and 51, from the reduction of ketone 49 which is 
available from the previously synthesized 46 (Scheme 18). 
 
Scheme 18.  Fifth retrosynthesis of the CAY-1 aglycone. 
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Since this synthetic strategy would require a stereoselective reduction of 3β-
benzyloxyspirostan-2-one (49) to an equatorial alcohol, literature methods reporting high 
yields for similar transformations were investigated.  Unfortunately, methods favoring 
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reductions to axial alcohols were much more developed with the most important 
breakthrough being the discovery of the bulky Selectride reducing agents.52  In general, 
an axial approach to a cyclic ketone is favored for hydrides to give the equatorial alcohol 
as the major product.  Although the equatorial product is more stable than the axial one, 
the main reason for this preference actually stems from the sterics of the hydride 
approach to the cyclic ketone (Scheme 19).  Additionally, orbital effects favor an axial 
approach of hydrides to cyclic ketones.53  Conversely, large hydrides are forced to 
approach cyclic ketones from the less sterically hindered equatorial position in spite of 
these orbital and torsional effects. 
 
Scheme 19.  Stereochemistry of hydride reductions of cyclic ketones.53 
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 In practice, however, especially when dealing with complex substrates, bulky 
hydrides tend to give higher yields and are more stereoselective in favoring axial alcohol 
formation as compared to the ability of small hydrides, such as NaBH4 and LiAlH4, to 
favor equatorial alcohols.  This was well illustrated in the synthesis of the CAY-1 
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aglycone reported by Holzapfel et al. in which the reduction of ketone 36 with NaBH4 
gave the equatorial alcohol 37 in only 63% yield (Scheme 20).  The authors were unable 
to improve the yield of this reaction by varying the solvents from methanol/THF to 
dioxane and, finally, 2-propanol. 
 
Scheme 20.  Literature reported reduction of cyclic ketone 36 with NaBH4.47 
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 Therefore, it seemed that a more promising way to favor the formation of the 
required equatorial C-2 alcohol of the CAY-1 aglycone would be to utilize a reduction 
that proceeds via the establishment of an equilibrium since the equatorial alcohol is 
thermodynamically the more stable product.  One such reaction is the Meerwein-
Ponndorf-Verley reduction.54  An example of the application of this reaction to a steroidal 
substrate was reported in a paper by Snaith et al. in which they describe the successful 
reduction of 5α-cholestan-3-one with Al-isopropoxydiisobutylalane (DIBAOiPr) at room 
temperature in toluene in 7 hours (Scheme 21).55   
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Scheme 21.  Literature reported reduction of 5α-cholestan-3-one using a Meerwein-
Ponndorf-Verley-type reaction.54,55 
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With this in mind, 3β-Benzyloxy-(22S,25R)-5α-spirostan-2β-ol (46) was prepared 
from hecogenin acetate (16) as described above and oxidized with chromic acid to give 
ketone 49 in 90% yield for this step.  Next, 49 was stirred at room temperature with 
DIBAOiPr in toluene for 6 hours as described by Snaith et al. but no product formation 
was observed and only about 5% conversion was noted by 1H NMR after 12 hours.  It has 
been reported that reductions with DIBAOiPr in diethyl ether require 5-7 days,56 most 
likely due to competition between the carbonyl of the substrate and the oxygen of the 
ether solvent for coordination to aluminum.57  Consequently, it was suspected that the 
presence of a cyclic acetal and a neighboring benzyl ether in substrate 49, both absent in 
the 5α-cholestan-3-one example, was extending the required reaction time for this ketone. 
 To explore the utility of Meerwein-Ponndorf-Verley-type reactions on spirostane 
ketones, spirostan-3-one (34) was stirred in toluene with 1 equivalent of DIBAOiPr.  
After 10 hours, the ketone of 34 was reduced to the equatorial alcohol of tigogenin (17) 
in 87% yield.  Furthermore, no axial alcohol formation was observed.  It was then clear 
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that the functional group interfering with the reduction of 49 was indeed the C-2 benzyl 
ether.  The reduction of 49 with DIBAOiPr in toluene was then repeated but 
unfortunately, even after 5 days only 50% conversion was observed by 1H NMR.  
Additionally, the reduction was forming a mixture of axial and equatorial alcohols of 50 
(Scheme 22). 
 
Scheme 22.a  Fifth attempted synthesis of the CAY-1 aglycone. 
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aReaction conditions: (a) H2CrO4, acetone, 30°C, 90%.  (b) DIBAOiPr, toluene, 5 days, ~50%. 
 
 
Summary of Approaches to the Synthesis of the CAY-1 Aglycone 
 In addition to the syntheses discussed above by Sondheimer et al. and by 
Holzapfel et al., Yu et al. published a 7 step synthesis of the CAY-1 aglycone from 
diosgenin in 28% yield (Scheme 23).58  Although their report is more recent than that of 
Holzapfel et al., it is less efficient in that it is both lower yielding and requires more 
steps.  Even so, it is worth highlighting the fact that these authors chose to invert the axial 
C-3 alcohol of 54 by oxidizing it to ketone 55 and then reducing it to the corresponding 
equatorial alcohol 56.  Yu et al. employed a Luche reduction and made no improvement 
on the yield of this step. 
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Scheme 23.  Literature reported synthesis of the CAY-1 aglycone by Yu et al.58 
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Overall, it has been determined that the synthesis of the CAY-1 aglycone from 
commercially available sterols is complicated by the difficulty in favoring equatorially 
oriented C-2 and C-3 alcohols either by substitution reactions or by reductions of 
corresponding ketones.  In the case of substitution reactions, this is due to the preference 
of nucleophiles for an axial approach in cyclic systems.  For reduction reactions, the 
complication arises from the neighboring oxygen which coordinates to the metal of 
hydride reducing agents and interferes with the progress and stereoselectivity of the 
reaction. 
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RESULTS AND DISCUSSION  
CAY-1 PENTASACCHARIDE MOIETY 
 
Initial Retrosynthetic Analysis of the CAY-1 Pentasaccharide 
 The CAY-1 pentasaccharide moiety is a 2,3-branched oligosaccharide consisting 
of four glucose units and one galactose unit, all linked by β-glycosidic bonds (Figure 6).  
Three of the glucose units are (1→3)-linked, one of which has an additional glucose unit 
at position 2.  This branched glucose unit is also bonded to the galactose unit by a (1→4)-
linkage. 
 
Figure 7.  CAY-1 Pentasaccharide Moiety. 
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 Originally, the synthesis of the CAY-1 pentasaccharide moiety was designed 
using a linear synthetic approach in which each of the five monosaccharide units would 
be added sequentially (Scheme 24).  In this way, pentasaccharide 57 would be available 
from a coupling between branched tetrasaccharide donor 58 and position 4 of galactosyl 
acceptor 59.  The axial orientation of position 4 of galactose makes it less reactive in 
glycosidic bond formation than corresponding equatorial alcohols.  Additionally, 
approaches toward favoring a β-glycosylation with an axial alcohol of a glycosyl acceptor 
would need to be explored for this step.  It should be noted that since this coupling would 
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be performed late in the pentasaccharide synthesis, the yield for this step would be of 
great concern.   
 
Scheme 24.a  Initial retrosynthesis of the CAY-1 pentasaccharide moiety. 
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aR = appropriate alcohol protecting groups.  L = appropriate leaving groups for glycosidic bond formation. 
 
The most difficult aspect of this approach to the pentasaccharide synthesis is the 
preparation of tetrasaccharide 58 from trisaccharide acceptor 60 and a glucosyl donor.  
The synthesis of trisaccharide 60 is complicated by the requirement for a protecting 
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group migration from C-2 to C-1 of the reducing end of trisaccharide 62 in order to 
prepare tetrasaccharide 58 by this route.  The linear (1→3)-linked trisaccharide 62 would 
be synthesized in turn from the glycosidic bond formation between disaccharide donor 63 
and position 3 of glucosyl acceptor 64.  Similarly, disaccharide 63 would be prepared 
from the coupling between glucosyl donor 61 and position 3 of glucosyl acceptor 64. 
In addition to the aforementioned protecting group migration, the other important 
aspects of the pentasaccharide synthesis that needed to be considered carefully include 
the protecting group and glycosylation method selections.  The complexity of 
glycosylation reactions makes it difficult, at best, to accurately predict what would be the 
most effective method to use for any given step in an oligosaccharide synthesis.  There 
are, however, several trends that can be used to design and optimize a synthetic strategy. 
While there are many well developed glycosylation methods for oligosaccharide 
synthesis, the vast majority of them follow the same general mechanism (Scheme 25).59-63  
In the presence of a promoter, the leaving group of the glycosyl donor is freed from the 
molecule.  The structure of the oxocarbenium intermediate formed depends on the nature 
of the C-2 substituent of the glycosyl donor.  Participating groups, such as alkyl or aryl 
esters and amides, can help stabilize the intermediate and tend to favor the formation of 
1,2-trans-glycosides.  It is important to note that in this case a side reaction occurs to 
form an orthoester.  Even though orthoester formation is reversible, it can still have a 
deleterious effect on the glycosylation depending on the nature of the glycosyl donor and 
acceptor and the reaction conditions. 
Glycosyl donors with non-participating groups at C-2, such as ethers, called 
armed donors, react faster than those with participating groups at C-2 (disarmed donors).   
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This is due to the fact that the C-2 substituent of an armed donor is less electron 
withdrawing than that of a disarmed donor and therefore the oxocarbenium intermediate 
forms faster.  In this case, the stereoselectivity of the glycosylation is largely solvent 
dependent. 
 
Scheme 25.  Generalized mechanism for glycosylation reactions.59 
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In ether solvents, armed donors generally give α-glycosides since ethers 
preferentially stabilize oxonium intermediates from an equatorial attack (Scheme 26).64 
The fact that the β-anomer of glucosyl ether oxonium ions is more stable than its 
corresponding α-anomer is in direct contrast to the anomeric effect and therefore is 
sometimes called the reverse anomeric effect.  The anomeric effect, a special case of the 
gauche effect, states that there is a general preference for gauche conformations about a 
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C-Y bond in an X-C-Y-C system where X and Y are heteroatoms with at least one 
nonbonding electron pair (Figure 7).65   
 
Scheme 26.  Glycosylation of an armed donor in diethyl ether.64 
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Figure 8.  The anomeric effect.65 
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Since anti conformations are sterically preferred, the anomeric effect will only be 
observed when stabilization by the anomeric effect is greater than all steric factors.66  The 
reverse anomeric effect is an observation that the axial orientation is more stable for 
positively charged heteroatoms bound to the anomeric carbon.  It should be noted that the 
existence of a reverse anomeric effect has been debated since there are many exceptions 
to this generalization.67,68 
One explanation for the anomeric effect is that there is less lone pair interaction 
between the substituent and the ring oxygen atom for gauche conformations (Figure 8).  
A second explanation is that the dipoles generated by the substituent and the ring oxygen 
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atom are in opposing directions in the axial anomer and they are in similar directions in 
the equatorial anomer.  Finally, the most widely accepted explanation for the anomeric 
effect is the stabilizing effect created by hyperconjugation between the axial lone pair on 
the ring oxygen atom and the σ* orbital of an axial heteroatom substituent on the 
anomeric carbon.  This type of stabilization by hyperconjugation is not possible when the 
substituent is equatorial.59 
 
Figure 9.  Explanations for the anomeric effect.59 
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 While glycosylations of armed donors in ether solvents give primarily α-
glycosides as described above, using acetonitrile as the solvent favors β-glycosides under 
kinetic conditions.69,70  If there is a reverse anomeric effect, the solvation of oxonium 
cation intermediates by acetonitrile would be an exception.  In this case, acetonitrile 
favors solvation from the axial face and therefore glycosylations performed with armed 
donors in acetonitrile produce β-glycosides (Scheme 27). 
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Scheme 27.  Glycosylation of an armed donor in acetonitrile.69 
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 In consideration of the CAY-1 pentasaccharide, the trichloroacetimidate 
glycosylation method (Scheme 28) was selected due to the fact that it is generally high 
yielding and highly stereoselective even in complex oligosaccharide syntheses.60,71-74  
The trichloroacetimidate donors are formed by the reaction of the anomeric alcohol with 
trichloroacetonitrile under basic conditions.  Strong bases, such as sodium hydride, and 
longer reaction times favor the formation of the thermodynamically more stable α-
trichloroacetimidate.  The stereoselectivity of the donor is important for SN2-type 
glycosylations which can be favored for the trichloroacetimidate method by using weaker 
promoters, such as BF3·OEt2.60 
 
Scheme 28.  Schmidt’s trichloroacetimidate method.60 
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 The retrosynthetic analysis of the CAY-1 pentasaccharide reveals the need for 
selectively protected glucosyl and galactosyl acceptors.  Specifically, a glucosyl acceptor 
in which only the C-3 alcohol is left unprotected is required.  This need is fulfilled by the 
commercially available saccharide 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
(diacetone D-glucose).  Additionally, a galactosyl acceptor in which only the C-4 alcohol 
is left unprotected will need to be prepared. 
 
HO
O
O
O
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1
3
2
5 64
65 (Diacetone D-glucose) 
 
Initial Approach to the Synthesis of the CAY-1 Pentasaccharide 
 To begin the synthesis, glucosyl trichloroacetimidate donor 69 was prepared in 
three steps in 33% yield following literature procedures with minor modifications 
(Scheme 29).75-78  In the first step, D-glucose (66) was protected as pentabenzoate 67.  
Next, the anomeric position of 67 was deprotected using 2-aminoethanol and then 
activated as trichloroacetimidate 69.  The glycosylation between diacetone D-glucose79 
and trichloroacetimidate donor 69 gave β-linked disaccharide 70 in only 53% yield.  It 
has been reported in the literature that glycosylations using diacetone D-glucose donors 
tend to be low yielding.75  This is likely due to the furanose ring which renders the C-3 
alcohol less reactive, much like an axial alcohol on a pyranose ring.   
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Nevertheless, since this donor is commercially available, it is conceivable that it 
would be more efficient to proceed with the diacetone D-glucose acceptor rather than 
prepare an acceptor that would give higher yields in glycosylations with 
trichloroacetimidate donors.  Therefore, the acetonide protection of disaccharide 70 was 
hydrolyzed under acidic conditions to give partially protected disaccharide 71 which was 
subsequently reprotected by reaction with benzoyl chloride to give fully protected 
disaccharide 72.  These steps were repeated to prepare trisaccharide 77 in eleven steps 
and 0.5% overall yield from D-glucose. 
 
Scheme 29.a  Synthesis of linear trisaccharide portion of CAY-1 pentasaccharide. 
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aReaction conditions: (a) BzCl, Py, 56% (67), 78% (72), 49% (77), (b) 2-aminoethanol, DMSO, EtOAc, 
70% (68), 40% (73), (c) Cl3CCN, K2CO3, DCM, 48 h, 83% (69), 94% (74) (d) 65, BF3·OEt2, DCM, 53% 
(70), 36% (75) (e) TFA, THF/H2O, 86% (71) , 67% (76). 
 
 
 In order to proceed with the synthesis of the CAY-1 pentasaccharide from 
trisaccharide 77, it was necessary to explore methodology that could be used to 
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selectively deprotect only the C-2 alcohol of the reducing sugar of the trisaccharide.  
Since the preparation of trisaccharide 77 requires so many steps and is low yielding, this 
conversion was explored for the monosaccharide D-glucose pentaacetate (78).  Following 
literature procedures with minor modifications, 1,3,4,6-tetra-O-acetyl-α-D-glucopyranose 
(81) was prepared in four steps and 16% yield from D-glucose (Scheme 30).76,80-82   
To begin, D-glucose was protected as pentaacetate 78.  Note that 78 is 
commercially available although its preparation from D-glucose using acetic anhydride in 
pyridine is straightforward.  Next, the anomeric alcohol of 78 was deprotected and 
converted to glucosyl chloride 80 using (1-chloro-2-methylpropenyl)-dimethylamine.  
Finally, the C-2 alcohol was deprotected via an acetate group migration from C-2 to C-1 
of 80 to give the desired tetraacetate 81. 
 
Scheme 30.a  Preparation of 1,3,4,6-tetra-O-acetyl-α-D-glucopyranose. 
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aReaction conditions: (a) Ac2O, Py, 83%, (b) 2-aminoethanol, DMSO, EtOAc, 70%, (c) (1-chloro-2-
methylpropenyl)-dimethylamine, CHCl3, (d) H2O, DMF/acetone, 27% (2 steps). 
 
 
 
At this point, there were two major concerns with this synthetic approach to the 
CAY-1 pentasaccharide moiety.  First, the preparation of the linear trisaccharide moiety 
required 11 steps to produce trisaccharide 77 in only 0.5% yield from D-glucose.  
Furthermore, based on the results of the preparation of monosaccharide tetraacetate 81, 
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deprotecting the C-2 alcohol of the reducing sugar of trisaccharide 77 in preparation for 
the next glycosylation would require three steps and the yield would likely be similar to 
the 19% yield achieved on the monosaccharide.   
In addition to yield, the second major concern was the stability of a glucosyl 
acceptor like 77 during a glycosylation reaction given the migratory aptitude of the 
acetate group.  In fact, acetate migration would likely occur to an appreciable extent and 
the result of the glycosylation would be a mixture of disaccharides, the intended product 
82, and 83 from the glycosylation of 81 with itself (Scheme 31).  Therefore, a new 
approach to the synthesis of the CAY-1 pentasaccharide moiety was needed. 
 
Scheme 31.  Possible acetate migration during glycosylations with acceptor 81. 
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Second Retrosynthetic Analysis of the CAY-1 Pentasaccharide 
 A search of the literature revealed that much progress has been made in an effort 
to improve the efficiency of syntheses of glycoconjugate natural products.83-85  
Specifically, Linhardt et al. reported the synthesis of disaccharide 85 from partially 
protected isopropyl (R)-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (84) and benzoyl 
protected trichloroacetimidate glucosyl donor 69 in 83% yield (Scheme 32).86  This result 
suggests that the C-3 alcohol of glucosyl acceptor 84 is more reactive in glycosylation 
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reactions than the C-2 alcohol.  Hoping to utilize this apparent difference in reactivity 
between these two alcohols, the synthesis of the CAY-1 pentasaccharide was redesigned. 
 
Scheme 32.  Literature reported usage of partially protected glucosyl acceptors by 
Linhardt et al.86 
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 In this new design, the CAY-1 pentasaccharide moiety 88 would be prepared 
from the glycosylation between thioglycoside donor 89 and galactosyl acceptor 90 
(Scheme 33).  Although tetrasaccharide donor 89 does not have a C-2 participating group 
to aid in favoring a (1,2)-trans linkage, the results reported by Linhardt et al. suggested 
that a stereoselective glycosylation might be achieved in this step.  In their case, Linhardt 
et al. reported success at favoring a β-glycosylation between armed thioglycoside donor 
86 and diosgenin (Scheme 32).87   
Thioglycosides are convenient tools in oligosaccharide synthesis since they can 
serve both as anomeric protecting groups and as anomeric activating groups depending 
on the promoter used during glycosylations.  For example, they can be used in 
conjunction with trichloroacetimidate methodology since thioglycosides are stable under 
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trichloroacetimidate promotion conditions.  When needed, they are activated using 
promoters such as a combination of N-iodosuccinimide and trimethylsilyl triflate.  In this 
way, once tetrasaccharide donor 89 is prepared, it could be used immediately in the next 
glycosylation reaction without the need for further deprotection and activation steps. 
 
Scheme 33.  Second retrosynthesis of the CAY-1 pentasaccharide moiety. 
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In addition to the efficiency of using thioglycosides as protecting and activating 
groups, the convergent preparation of branched tetrasaccharide 89 would be a more 
practical approach as compared to the previously described linear retrosynthesis.  Using 
partially protected glucosyl acceptor 84, tetrasaccharide 89 could be prepared by 
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sequential glycosylations with trichloroacetimidate donors 74 and 69 without the need for 
additional deprotection or activation steps. 
Second Approach to the Synthesis of the CAY-1 Pentasaccharide 
 Before attempting to synthesize the CAY-1 pentasaccharide moiety using the new 
approach, it was necessary to verify this methodology on smaller oligosaccharides.  This 
would allow for easier characterization by 1H NMR spectroscopy.  Partially protected 
glucosyl acceptor 84 was prepared from β-D-glucose pentaacetate 78 in three steps and 
51% yield using literature procedures with minor modifications (Scheme 34).88,89  β-D-
glucose pentaacetate 78 reacts with 2-propanethiol in the presence of BF3·OEt2 to give 
the β-anomer of thioglucopyranoside 92.   
 
Scheme 34.a  Synthesis of 2,3-branched trisaccharide 94. 
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aReaction conditions: (a) propane-2-thiol, BF3·OEt2, DCM, (b) NaOH, MeOH/DCM, (c) 
dimethoxymethylbenzene, CSA, DMF, 51% (3 steps), (d) 69, TMSOTf, DCM, 23% (2 steps). 
 
 
It is important to proceed at this point with only one anomer in order to make it 
possible to characterize the products of the glycosylations by 1H NMR since α- and β-
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anomers give different spectra.  The acetate protecting groups of 92 were then hydrolyzed 
with NaOH in MeOH/DCM and the C-4 and C-6 alcohols of the resulting thioglycoside 
93 were then protected as a benzylidene acetal to give thioglycoside donor 84.  
Trichloroacetimidate donor 69 was prepared from D-glucose as described above and then 
reacted twice with donor 84 using trimethylsilyl triflate as the promoter to give 2,3-
branched trisaccharide 94 in 23% yield for the two glycosylations.   
Disaccharide 85 was isolated and characterized before the second glycosylation 
reaction was performed in order to verify the difference in reactivity for the C-2 and C-3 
alcohols of 84.  The yield for these glycosylations was not of concern since it was 
reduced by the isolation of intermediate 85 for characterization.  For the pentasaccharide 
synthesis, the two glycosylations with donor 84 would be performed in one pot to prepare 
2,3-branched tetrasaccharide 89. 
 The next step was to verify the stereoselectivity of a glycosylation between 
trisaccharide donor 94 and the C-4 alcohol of a galactosyl acceptor 90.  Due to the axial 
orientation of the C-4 alcohol of galactose, it is possible to prepare 1,2,3,6-tetra-O-
benzoyl-α-D-galactopyranose (90) in one step by the slow addition of four equivalents of 
benzoyl chloride to an ice-cold solution of D-galactose in pyridine.90,91  Trisaccharide 
donor 94 was then reacted with galactosyl acceptor 90 under NIS-TMSOTf promotion.  
Unlike trichloroacetimidates, in order to activate thioglycosides, a thiophilic promoter 
such as NIS is needed.  Unfortunately, the glycosylation was not stereoselective and both 
α- and β-glycosides of tetrasacchcaride 95 were obtained. 
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Scheme 35. Glycosylation of trisaccharide donor 94 with galactosyl acceptor 90.  
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 At this point, it was suspected that the glycosylation between 94 and 90 was not 
stereoselective due to the lack of a participating group at C-2 of glycosyl donor 94.92-94  
Therefore, isopropyl tetra-O-acetyl-1-thio-β-D-glucopyranoside (92) was reacted with 
galactosyl acceptor 90 under NIS-TMSOTf promotion with the expectation that this 
disarmed donor would furnish the desired 1,2-trans glycoside by neighboring group 
participation (Scheme 36).  However, this glycosylation afforded the α-glycoside 96 as 
the major product in 74% yield. 
 In order to finally favor a β-glycosylation with galactosyl acceptor 90 using the 
trichloroacetimidate method, imidate 97 was prepared from 2,3,4,6-tetra-O-acetyl-D-
glucopyranose (79) and reacted with 90 under TMSOTf promotion.  This reaction 
furnished β-glycoside 98 in 37% yield.   
 
 
 
 
 
 
 
 61
Scheme 36.  Glycosylations of galactosyl acceptor 90 with thioglycoside 92 and 
trichloroacetimidate 97. 
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The characterization of 96 and 98 by 1H NMR spectroscopy is straightforward 
due to the difference in coupling constants for the H-1’ doublets of the non-reducing 
sugar unit of the disaccharides (Figure 9).  For α-linked 96, the J value for H-1’ is smaller 
(2.4 Hz) than the J value for the H-1’ doublet of β-linked 98 (3.8 Hz). 
 
 
 
 
 
 
 
 
 
 
 
 62
Figure 10.  1H NMR (400 MHz, CDCl3) comparison of 96 and 98. 
 
 
 
 
Summary of Approaches toward the CAY-1 Pentasaccharide Synthesis 
 While progress toward the synthesis of glycoconjugates containing 2,3-branched 
oligosaccharides has been reported in the literature, the reported syntheses describe 
glycoconjugates in which the aglycone is attached to the 2,3-branched unit of the 
oligosaccharide.95-97  The CAY-1 pentasaccharide moiety, however, has a galactose unit 
between the 2,3-branched unit and the aglycone, complicating the synthesis.  
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Nonetheless, isopropyl (R)-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (84) has been 
shown to be effective in the efficient synthesis of the 2,3-branched moiety of the target 
pentasaccharide.   
Additionally, it has been determined that a β-glycosylation with 1,2,3,6-tetra-O-
acetyl-α-D-galactopyranose (90) can be achieved using a disarmed trichloroacetimidate 
donor despite the fact that α-glycosylations are strongly favored for this acceptor.  This is 
likely due to the fact that the C-4 alcohol of the galactosyl acceptor is less reactive 
because it is in an axial orientation.  Finally, the glycosylation with galactose ought to be 
performed early in the synthesis of the pentasaccharide moiety because it is low-yielding. 
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CONCLUSION 
 
The syntheses of the aglycone and pentasaccharide moieties of CAY-1 are both 
challenging endeavors requiring many stereoselective steps.  It has been determined that 
the most efficient approach to the synthesis of the CAY-1 aglycone is via the epoxidation 
of the trimethylsilyl enol ether of spirostan-3-one.  However, further research is required 
to develop a highly stereoselective method for the reduction of C-2 and C-3 ketones with 
neighboring ether groups.   
Through this work, several partially protected stereoisomers of the CAY-1 
aglycone have been prepared which can be used for the synthesis of saponin derivatives 
of CAY-1 for structure-activity relationship studies.  Definitive characterization of one of 
these isomers, 3α-hydroxy-(22S,25R)-5α-spirostan-2β-yl acetate (32), was achieved by 
X-ray crystallography.  Such derivatives would be important not only for optimization of 
biological activity, but also for elucidation of the mechanism of action of CAY-1. 
Furthermore, a quantitative inversion of the C-3 stereochemical configuration of 
32 was achieved via an acetate group migration of the corresponding mesylate.  The 
possibility of competition between the acetate migration and substitution mechanisms 
with various nucleophiles was explored.  The results, however, indicate that this 
inversion only occurs via the acetate migration.  The successful inversion of this 
stereocenter has not been previously reported by any method other than through an 
oxidation-reduction sequence with yields not exceeding 63%.33,47,58 
Additionally, the CAY-1 pentasaccharide moiety poses two significant 
challenges.  The first is the inclusion of a central 2,3-branched moiety.  It has been 
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determined that this can be synthesized efficiently from the partially protected isopropyl 
(R)-4,6-O-benzylidene-1-thio-β-D-glucopyranoside acceptor since the C-2 and C-3 
alcohols differ in their reactivity in glycosylation reactions.  Utilization of this partially 
protected glycosyl acceptor intermediate is crucial since it allows for a convergent, and 
therefore more efficient, approach to the synthesis of this 2,3-branched oligosaccharide. 
The second challenge is the β-(1→4) linkage to the galactosyl acceptor.  This 
significantly increases the complexity of the synthesis of the CAY-1 pentasaccharide as 
compared to literature reported syntheses of other branched oligosaccharides.  It has been 
determined that this is due to the fact that a β-linkage is disfavored for the C-4 alcohol of 
galactose since it is axial and therefore reacts slowly.  This creates a tendency for the 
thermodynamically more stable α-glycoside to form.  Nonetheless, this β-(1→4) linkage 
was achieved using a disarmed trichloroacetimidate glucosyl donor. 
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EXPERIMENTAL 
General Information 
 All chemicals were purchased from Aldrich Chemical Co., Milwaukee, WI, and 
used as received unless otherwise noted.  Anhydrous CH2Cl2, 1,2-dimethoxyethane, 3-
bromopropyne, 1.5 M solution of lithium diisopropylamide in toluene, and 
chlorotrimethylsilane were purchased in sure-seal bottles from Aldrich Chemical Co.  
Chromatography refers to column chromatography on silica gel (Sorbent Technologies 
Silica Gel, 60 Å, 32 – 63 µm Standard Grade).  1H and 13C NMR spectra were recorded 
on a Varian-Gemini 400 MHz spectrometer or, as noted, on a Varian-Gemini 300 or 500 
MHz multiprobe spectrometer.  Deuterated chloroform (CDCl3) and dimethyl sulfoxide 
(d6-DMSO) were purchased from Cambridge Isotope Laboratories, Inc.  Mass spectra 
were recorded using a Micromass Quattro-II triple quadropole mass spectrometer. 
 
(22S,25R)-5α-Spirostan-3β-ol (17, tigogenin)36:  Hecogenin acetate (1.0 g, 2.1 mmol) 
and hydrazine hydrate (1.0 mL, 20 mmol) were stirred in 2-ethoxyethanol (10 mL) under 
an atmosphere of nitrogen for 20 minutes at room temperature and then refluxed for 1 
hour.  The mixture was cooled to room temperature before KOH (1.0g, 18 mmol) was 
added.  The mixture was heated to 136°C, refluxed for 3 hours and then cooled to room 
temperature.  Concentrated HCl was added to neutralize the mixture and the resulting 
white solid was filtered and washed with water to give spirostan 17 (860 mg, 98 % yield).  
Selected 1H NMR (400 MHz, CDCl3): δ 4.38 (q, J = 11.2 Hz, 1H), 3.58 (m, 1H), 3.47 (m, 
1H), 3.37 (t, J = 10.8 Hz, 1H), 0.96 (d, J = 3.4 Hz, 3H), 0.82 (s, 3H), 0.79 (d, J = 3.2 Hz, 
3H), 0.76 (s, 3H).  13C NMR (400 MHz, CDCl3): δ 109.5, 81.0, 71.5, 67.0, 62.3, 56.5, 
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54.5, 45.0, 41.8, 40.7, 40.2, 38.4, 37.1, 35.7, 35.3, 32.4, 31.9, 31.7, 31.5, 30.5, 29.0, 28.8, 
21.2, 17.3, 16.7, 14.7, 12.5. 
(22S,25R)-5α-Spirost-2-ene (27)37-39:  NaH (5.8 mg, 0.24 mmol) was stirred in THF (10 
mL).  Tigogenin (17) (100 mg, 0.24 mmol) was added and stirred at room temperature 30 
minutes.  Carbon disulfide (130 mg, 1.7 mmol) was added and stirred another 2 hours.  3-
Bromopropyne (140 mg, 1.2 mmol) was added and the mixture was stirred an additional 
3 hours at room temperature.  The reaction was quenched with saturated NH4Cl (40 mL), 
extracted with CH2Cl2 (3 x 50 mL), and the organic layers were combined and dried over 
sodium sulfate.  The solvents were removed under reduced pressure and the residue was 
purified by flash column chromatography (1:1 ethyl acetate: hexanes) to give propargyl 
xanthate ester 28 which was used immediately in the following reaction.  Selected 1H 
NMR of 28 (500 MHz, CDCl3): δ 5.50 (m, 1H), 4.40 (q, J = 11.3 Hz, 1H), 3.85 (s, 1H), 
3.82 (s, 1H), 3.48 (m, 1H), 3.38 (t, J = 11.0 Hz, 1H), 0.97 (d, J = 3.5 Hz, 3H), 0.88 (s, 
3H), 0.80 (d, J = 3.0 Hz, 3H), 0.77 (s, 3H).  Trifluoromethanesulfonic acid (1.0 mL, 11 
mmol) and 2,4,6-trimethylpyridine (1.5 mL, 11 mL) were stirred at 0°C in diethyl ether 
(5 mL).  A portion of the resulting sulfonate salt (7.0 mg, 0.02 mmol) was transferred to a 
solution of propargyl xanthate ester 28 (0.24 mmol) in toluene (10 mL).  The reaction 
was refluxed 30 hours, cooled to room temperature, and the solvent was removed under 
reduced pressure.  The resulting solid was purified by flash column chromatography 
(1:10 ethyl acetate: hexanes) to give 27 as a white solid (86 mg, 89 % yield over 2 steps 
from 18).  Selected 1H NMR (300 MHz, CDCl3): δ 5.56 (m, 2 H), 4.37 (q, J = 11.2 Hz, 
1H), 3.45 (m, 1H), 3.35 (t, J = 10.4 Hz, 1H), 0.94 (d, J = 3.8 Hz, 3H), 0.78 (s, 3H), 0.75 
(s, 3H), 0.75 (d, J = 3.2 Hz, 3H).  13C NMR (400 MHz, CDCl3): δ 126.0, 109.4, 81.0, 
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67.0, 62.4, 56.5, 54.2, 41.8, 41.6, 40.6, 40.2, 39.9, 35.4, 34.9, 32.2, 32.1, 31.9, 31.6, 30.5, 
29.9, 29.0, 28.8, 20.9, 17.3, 16.6, 14.7, 11.9.  Alternatively, 27 was prepared from 17 via 
methyl xanthate ester 29.  Sodium hydride (10 mg, 0.42 mmol) was suspended in THF 
(10 mL).  Tigogenin (17) (100 mg, 0.24 mmol) was added and stirred at room 
temperature 30 minutes.  Carbon disulfide (130 mg, 1.7 mmol) was added and stirred 
another 2 hours.  Methyl iodide (170 mg, 1.2 mmol) was added and the mixture was 
stirred an additional 3 hours at room temperature.  The reaction was quenched with 
saturated NH4Cl (40 mL), extracted with CH2Cl2 (3 x 50 mL), and the organic layers 
were combined and dried over sodium sulfate.  The solvents were removed under reduced 
pressure and the residue was purified by flash column chromatography (1:15 ethyl 
acetate: hexanes) to give methyl xanthate ester 29 which was used immediately in the 
following reaction.  Selected 1H NMR of 29 (400 MHz, CDCl3): δ 5.47 (m, 1H), 4.37 (q, 
J = 11.4 Hz, 1H), 3.45 (m, 1H), 3.35 (t, J = 10.8 Hz, 1H), 2.52 (s, 3H), 0.94 (d, J = 3.6 
Hz, 3H), 0.85 (s, 3H), 0.77 (d, J = 3.2 Hz, 3H), 0.74 (s, 3H).  Methyl xanthate ester 29 
was heated at 200°C for 2 hours under reduced pressure.  The resulting solid was purified 
by flash column chromatography (1:10 ethyl acetate: hexanes) to give 27 as a white solid 
(90 mg, 94 % yield). 
2,3-Epoxy-(22S,25R)-5α-spirostan (26):  Spirostene 27 (4.4 g, 11 mmol) was dissolved 
in anhydrous CH2Cl2 (90 mL) under an atmosphere of nitrogen.  To this solution, m-
CPBA (2.1 g, 12 mmol) was added and the mixture was stirred 30 minutes at room 
temperature.  5 % Na2SO3 (100 mL) was added and the mixture was stirred an additional 
15 minutes.  The organic layer was separated and the aqueous phase was extracted with 
CH2Cl2 (3 x 100 mL).  The organic phases were combined and washed with saturated 
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NaHCO3 (100 mL), followed by brine (100 mL), and dried over sodium sulfate.  The 
solvent was removed under reduced pressure and the resulting solid was purified by flash 
column chromatography (1:5 ethyl acetate: hexanes) to give 26α as a white solid (4.2 g, 
91 % yield).  Selected 1H NMR of 26α (400 MHz, CDCl3): δ 4.36 (q, J = 11.2 Hz, 1H), 
3.45 (m, 1H), 3.35 (t, J = 10.8 Hz, 1H), 3.13 (br s, 1H), 3.09 (m, 1H), 0.94 (d, J = 3.6 Hz, 
3H), 0.77 (d, J = 3.4 Hz, 3H), 0.75 (s, 3H), 0.73 (s, 3H).  13C NMR of 26α (400 MHz, 
CDCl3): δ 109.4, 80.9, 67.0, 62.3, 56.3, 53.8, 52.5, 51.1, 41.8, 40.5, 40.1, 38.4, 36.4, 
35.4, 33.9, 32.0, 31.9, 31.5, 30.4, 29.2, 29.0, 28.5, 20.8, 17.3, 16.5, 14.7, 13.1.  1H NMR 
26β (300 MHz, CDCl3): δ 4.37 (q, J = 11.2 Hz, 1H), 3.46 (m, 1H), 3.35 (t, J = 10.8 Hz, 
1H), 3.14 (m, 1H), 3.03 (d, J = 2.9 Hz, 1H), 1.04 (s, 3H), 0.93 (d, J = 3.3 Hz, 3H), 0.79 
(d, J = 3.2 Hz, 3H), 0.76 (s, 3H). 
3α-Hydroxy-(22S,25R)-5α-spirostan-2β-yl acetate (32):  Epoxide 26α (100 mg, 0.24 
mmol) was refluxed in acetic acid (10 mL) for 2 hours.  The solution was co-evaporated 
with toluene (3 x 5 mL) and the resulting solid was purified by gravity column 
chromatography (1:4 ethyl acetate: hexanes) to give 32 as a white solid (77 mg, 84 % 
yield).  Selected  1H NMR (400 MHz, CDCl3): δ 4.87 (br s, 1H), 4.38 (q, J = 11.2 Hz, 
1H), 3.84 (br s, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 2.04 (s, 3H), 0.95 (d, J = 3.4 
Hz, 3H), 0.92 (s, 3H), 0.78 (d, J = 3.2 Hz, 3H), 0.75 (s, 3H).  13C NMR (400 MHz, 
CDCl3): δ 170.5, 109.5, 81.0, 73.3, 67.7, 67.0, 62.3, 56.4, 55.1, 41.8, 40.7, 40.2, 38.7, 
37.3, 35.9, 34.8, 32.2, 32.0, 31.9, 31.5, 30.5, 29.0, 28.2, 21.6, 20.8, 17.3, 16.7, 14.7, 13.9. 
(22S,25R)-5α-Spirostan-3-one (34)47: Tigogenin (17) (1 g, 2.40 mmol) was dissolved in 
acetone (50 mL) at 30°C.  8N Chromic acid in 40% H2SO4 (2.5 mL) was added and the 
mixture was stirred for 30 minutes.  Water (100 mL) was added and the resulting solid 
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was filtered and washed with water and purified by flash column chromatography (1:2 
ethyl acetate: hexanes) to give 34 as a white solid (930 mg, 93 % yield) which was used 
immediately in the next reaction.  Selected 1H NMR (400 MHz, CDCl3): δ 4.39 (q, J = 
11.2 Hz, 1H), 3.46 (m, 1H), 3.36 (t, J = 10.8 Hz, 1H), 1.02 (s, 3H), 0.96 (d, J = 3.6 Hz, 
3H), 0.78 (s, 3H), 0.78 (d, J = 2.0 Hz, 3H).  13C NMR (400 MHz, CDCl3): δ 212.1, 109.4, 
80.9, 67.0, 62.4, 56.3, 54.0, 46.8, 44.8, 41.8, 40.7, 40.1, 38.7, 38.3, 35.9, 35.2, 32.0, 31.9, 
31.5, 30.4, 29.0, 29.0, 21.4, 17.3, 16.6, 14.7, 11.7.   
[(22S,25R)-5α-Spirost-2-enyl-3-oxy]-trimethylsilane (35)47: Ketone 34 (410 mg, 1.0 
mmol) was dissolved in anhydrous 1,2-dimethoxyethane (10 mL) under an atmosphere of 
nitrogen.  The mixture was cooled to 0°C and LDA (1.5 M solution in toluene, 1.3 mL, 
2.0 mmol) was added and stirred 10 minutes.  Chlorotrimethylsilane (0.66 mL, 5.0 mmol) 
was added and the mixture was stirred 2 hours at room temperature.  Triethylamine (4 
mL) and saturated NaHCO3 solution (10 mL) were added and the mixture was extracted 
with CH2Cl2 (3 x 20 mL).  The organic fractions were combined, dried over sodium 
sulfate, and the solvents were removed under reduced pressure.  The residue was purified 
by flash column chromatography (20:1 hexanes: ethyl acetate) to give trimethylsilyl enol 
ether 35 as a white solid (370 mg, 76 % yield).  Selected 1H NMR (400 MHz, CDCl3): δ 
4.76 (d, J = 2.8 Hz, 1H), 4.40 (q, J = 11.6 Hz, 1H), 3.48 (m, 1H), 3.38 (t, J = 10.8 Hz, 
1H), 0.97 (d, J = 3.6 Hz, 3H), 0.79 (d, J = 3.2 Hz, 3H), 0.77 (s, 3H), 0.77 (s, 3H), 0.18 (s, 
9H). 
2β-Hydroxy-(22S,25R)-5α-spirostan-3β-yl acetate (42) and 3β-Hydroxy-(22S,25R)-
5α-spirostan-2β-yl acetate (43):  Spirostan 32 (470 mg, 1.0 mmol), methanesulfonyl 
chloride (0.15 mL, 1.5 mmol) and triethylamine (0.25 mL, 1.8 mmol) were stirred at 0°C 
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in anhydrous CH2Cl2 (15 mL) under an atmosphere of nitrogen for 2 hours.  The reaction 
was quenched with ice-cold HCl (1 M, 50 mL) and extracted with CH2Cl2 (3 x 50 mL).  
The organic layers were combined, washed with 50 mL water, and dried over sodium 
sulfate.  The solvent was removed under reduced pressure to give mesylate 41 as a white 
solid which was used immediately in the next reaction without further purification (460 
mg, 83 % yield).  Selected 1H NMR of 41 (300 MHz, CDCl3): δ 4.99 (br s, 1H), 4.68 (br 
s, 1H), 4.40 (q, J = 11.6 Hz, 1H), 3.48 (m, 1H), 3.37 (t, J = 11.1 Hz, 1H), 3.08 (s, 3H), 
0.96 (d, J = 3.5 Hz, 3H), 0.94 (s, 3H), 0.79 (d, J = 3.2 Hz, 3H), 0.76 (s, 3H).  Meslyate 41 
(50 mg, 0.09 mmol) and water (5 mL) were refluxed in pyridine (20 mL) for 7 hours.  
The solvent was removed under reduced pressure and the product was co-evaporated with 
toluene (3 x 5 mL) and purified by flash column chromatography (1:4 → 1:1 ethyl 
acetate: hexanes) to give 42 and 43 as a white solid (10 % 42, 90% 43, 42 mg, 97 % 
yield).  Selected 1H NMR of 42 (400 MHz, CDCl3): δ 4.78 (m, 1H), 4.39 (q, J = 11.2 Hz, 
1H), 4.10 (br s, 1H), 3.66 (m, 1H), 3.38 (t, J = 10.8 Hz, 1H), 2.09 (s, 3H), 1.06 (s, 3H), 
0.96 (d, J = 3.4 Hz, 3H), 0.79 (d, J = 3.0 Hz, 3H), 0.77 (s, 3H).  13C NMR of 42 (400 
MHz, CDCl3): δ 170.3, 109.4, 81.0, 75.7, 68.8, 67.0, 62.3, 56.3, 55.3, 45.6, 43.1, 41.7, 
40.8, 40.1, 35.6, 34.6, 32.2, 31.9, 31.5, 30.4, 28.9, 28.7, 28.2, 21.5, 21.2, 17.3, 16.7, 14.7, 
14.6.  Selected 1H NMR of 43 (400 MHz, CDCl3): δ 5.14 (br s, 1H), 4.39 (q, J = 11.4 Hz, 
1H), 3.69 (m, 1H), 3.47 (m, 1H), 3.37 (t, J = 10.8 Hz, 1H), 2.10 (s, 3H), 0.96 (d, J = 3.4 
Hz, 3H), 0.93 (s, 3H), 0.79 (d, J = 3.0 Hz, 3H), 0.76 (s, 3H).  13C NMR of 43 (400 MHz, 
CDCl3): δ 171.5, 109.5, 81.0, 73.5, 71.4, 67.0, 62.3, 56.3, 55.1, 45.4, 41.8, 41.2, 40.8, 
40.1, 35.6, 34.7, 33.2, 32.2, 31.9, 31.5, 30.4, 28.9, 28.3, 21.6, 21.3, 17.3, 16.7, 14.6, 14.5.  
Under an atmosphere of nitrogen, steroid 42 (30 mg, 0.063 mmol) was dissolved in 
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anhydrous CH2Cl2 (3 mL) and cooled to 0°C before triethylamine (16 µL, 0.095 mmol) 
and methanesulfonyl chloride (10 µL, 0.095 mmol) were added and stirred for 2 hours.  
Ice-cold HCl (1 M, 10 mL) was added and the mixture was extracted with CH2Cl2 (3 x 15 
mL).  The combined organic fractions were dried over sodium sulfate and the solvents 
were removed under reduced pressure to give mesylate 44 as a white solid which was 
used immediately in the next reaction without further purification.  Mesylate 44 and 
water (5 mL) were refluxed overnight in pyridine (20 mL).  The solvents were removed 
under reduced pressure and the resulting yellow solid was purified by flash column 
chromatography (1:4 → 1:1 ethyl acetate: hexanes) to give 42 and 43 as a white solid (20 
% 42, 80 % 43, 22 mg, 73 % yield in 2 steps from 42). 
3β-Benzyloxy-(22S,25R)-5α-spirostan-2β-ol (46):  Steroid 43 (90 mg, 0.19 mmol) was 
dissolved in dioxane (10 mL) and stirred 1 hour with 4Å molecular sieves.  Benzyl 
trichloroacetimidate (120 µL, 0.63 mmol) and trifluoromethanesulfonic acid (13 µL, 0.15 
mmol) were added and the reaction was stirred in an icebath for 1 minute and then at 
room temperature for 5 minutes.  Saturated NaHCO3 (10 mL) was added and the mixture 
was extracted with ethyl acetate (3 x 15 mL) and the combined organic fractions were 
dried over sodium sulfate.  The solvents were removed under reduced pressure and the 
resulting residue was purified by flash column chromatography (ethyl acetate: hexanes 
1:4 to 1:2) to give 3β-Benzyloxy-(22S,25R)-5α-spirostan-2β-yl acetate (47) as a white 
solid which was used immediately in the next reaction (83 mg, 78 % yield).  Selected 1H 
NMR of 47 (400 MHz, CDCl3): δ 7.38 – 7.32 (m, 5H), 5.42 (br s, 1H), 4.60 (d, J = 6.0 
Hz, 1H), 4.48 (d, J = 6.0 Hz, 1H), 4.39 (q, J = 11.2 Hz, 1H), 3.47 (m, 1H), 3.37 (t, J = 
11.2 Hz, 1H), 3.37 (m, 1H), 0.93 (d, J = 3.4 Hz, 3 H), 0.93 (s, 3H), 0.76 (d, J = 3.2 Hz, 
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3H), 0.73 (s, 3H).  Steroid 47 (83 mg, 0.15 mmol) was dissolved in methanol (15 mL).  
NaOH (1 N, 1 mL) was added and the mixture was refluxed overnight.  The mixture was 
neutralized with acidic Dowex resin and the resin was filtered and washed with additional 
methanol.  The solvents were removed under reduced pressure and the resulting solid was 
co-evaporated with toluene (3 x 5 mL) to give 46 as a white solid (73 mg, 96 % yield).  
Under an atmosphere of nitrogen, steroid 46 (60 mg, 0.12 mmol) was dissolved in 
anhydrous CH2Cl2 (10 mL) and cooled to 0°C before triethylamine (38 µL, 0.230 mmol) 
and methanesulfonyl chloride (23 µL, 0.230 mmol) were added and stirred for 2 hours.  
Ice-cold HCl (1 M, 50 mL) was added and the mixture was extracted with CH2Cl2 (3 x 50 
mL).  The combined organic fractions were dried over sodium sulfate and the solvents 
were removed under reduced pressure.  The residue was purified by flash column 
chromatography (1:4 ethyl acetate: hexanes) to give mesylate 45 as a white solid (55 mg, 
81 % yield) which was used immediately in the next reaction.  Mesylate 45 and water (5 
mL) were refluxed overnight in pyridine (20 mL).  The solvents were removed under 
reduced pressure and the resulting yellow solid was purified by flash column 
chromatography (1:4 ethyl acetate: hexanes) to give 46 as a white solid (43 mg, 90 % 
yield).  Selected 1H NMR of 46 (400 MHz, CDCl3): δ 7.37 – 7.30 (m, 5H), 4.57 (d, J = 
2.6 Hz, 2H), 4.36 (q, J = 11.2 Hz, 1H), 4.12 (br s, 1H), 3.45 (m, 1H), 3.38 (m, 1H), 3.35 
(t, J = 11.2 Hz, 1H), 1.01 (s, 3H), 0.93 (d, J = 3.4 Hz, 3H), 0.77 (d, J = 3.2 Hz, 3H), 0.74 
(s, 3H). 
3β-Benzyloxy-(22S,25R)-5α-spirostan-2-one (49): Steroid 36 (50 mg, 0.096 mmol) was 
dissolved in acetone (10 mL) at 30°C.  8N Chromic acid in 40% H2SO4 (1.0 mL) was 
added and the mixture was stirred for 30 minutes.  Water (20 mL) was added and the 
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resulting solid was filtered and washed with water and purified by flash column 
chromatography (1:2 ethyl acetate: hexanes) to give 49 as a white solid (44 mg, 90 % 
yield).  Selected 1H NMR (400 MHz, CDCl3): δ 7.37 – 7.28 (m, 5H), 4.86 (d, J = 6.0 Hz, 
1H), 4.52 (d, J = 6.0 Hz, 1H), 4.40 (q, J = 11.0 Hz, 1H), 3.95 (m, 1H), 3.46 (m, 1H), 3.37 
(t, J = 10.8 Hz, 1H), 0.96 (d, 3.4 Hz, 3H), 0.80 (d, J = 3.2 Hz, 3H), 0.79 (s, 3H), 0.76 (s, 
3H). 
Penta-O-benzoyl-β-D-glucopyranose (67)75:  D-glucose (5.0 g, 28 mmol) was refluxed 
in pyridine (100 mL) for 1 hour.  The solution was then added to benzoyl chloride (20 
mL) which had been heated to 65°C.  After the mixture was cooled to room temperature, 
water (400 mL) was added and stirred until the product solidified, approximately 30 
minutes.  The solid was filtered and washed with water and recrystallized from ethyl 
acetate to give 67 as a white solid (11 g, 56 % yield).  1H NMR (300 MHz, CDCl3): δ 
8.01 (d, J = 4.0 Hz, 4H), 7.89 (d, J = 3.8 Hz, 4H), 7.84 (d, J = 3.9 Hz, 2H), 7.53 – 7.21 
(m, 15 H), 6.28 (d, J=3.9 Hz, 1H), 6.02 (t, J = 9.3 Hz, 1H), 5.83 (q, J=12.9 Hz, 2H), 4.64 
(dd, J1  = 6.0 Hz, J2 = 1.4 Hz, 1H), 4.49 (dd, J1  = 8.1 Hz, J2 = 2.1 Hz, 1H), 4.394 (m, 
1H).  13C NMR (300 MHz, CDCl3): δ 166.3, 165.8, 165.30, 165.28, 164.8, 134.0, 133.7, 
133.6, 133.5, 133.3, 130.4, 130.0, 129.99, 129.96, 129.7, 128.9, 128.84, 128.82, 128.7, 
128.62, 128.59, 128.5, 92.9, 73.3, 73.0, 71.0, 69.2, 62.8. 
2,3,4,6-Tetra-O-benzoyl-D-glucopyranose (68)76:  Pentabenzoyl-δ-D-glucopyranose 67 
(10 g, 14 mmol) and 2-aminoethanol (2.0 g, 36 mmol) were stirred at room temperature 
in ethyl acetate (150 mL) and DMSO (2 mL) overnight, during which time the initial 
suspension formed a solution.  The resulting solution was washed with water (3 x 150 
mL) and the organic layer was dried over sodium sulfate and concentrated.  The residue 
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was purified by flash column chromatography (CH2Cl2 followed by Et2O) to give 68 as a 
white solid (6.0 g, 70 % yield).  100 mg of the product was recrystallized from diethyl 
ether/hexanes for 1H and 13C NMR analysis.  1H NMR (300 MHz, CDCl3) 68β: δ 8.19-
7.82 (m, 8H), 7.57-7.19 (m, 12H), 6.23 (t, J=9.9 Hz, 1H), 5.72 (m, 2H), 5.30 (dd, J1=6.45 
Hz, J2=1.2 Hz, 1H), 4.66 (m, 2H), 4.46 (dd, J1=8.6 Hz, J2=2.4 Hz, 1H), 3.12 (d, J=1.3 
Hz, 1H).  13C NMR of 68β (CDCl3): δ 166.6, 166.13, 166.10, 165.5, 133.6, 133.5, 133.3, 
130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.46, 
90.6, 72.5, 70.4, 69.6, 67.8, 63.0. 
O–(Tetra-O-benzoyl-α-D-glucopyranosyl)-trichloroacetimidate (69)77:  Tetrabenzoyl-
D-glucopyranose 68 (2.0 g, 3.3 mmol), K2CO3 (1.1 g, 8.2 mmol), and trichloroacetonitrile 
(5 mL) were stirred at room temperature in dichloromethane (20 mL) for 48 hours.  The 
resulting suspension was filtered through silica gel using a 1:1 mixture of CH2Cl2 and 
Et2O (150 mL).  The filtrate was concentrated to give 69 as a pale yellow solid (2.0 g, 83 
% yield).  1H NMR (300 MHz, CDCl3): δ 8.62 (s, 1H) 8.02 (d, J = 3.9 Hz, 2H), 7.93 (br 
d, J = 5.7 Hz, 4H), 7.85 (d, J = 4.2 Hz, 2H), 7.56 – 7.25 (m, 12H), 6.82 (d, J = 2.0 Hz, 
1H), 6.25 (t, J = 9.9 Hz, 1H), 5.79 (t, J=9.9 Hz, 1H), 5.60 (dd, J1 = 5.1 Hz, J2 = 1.8 Hz, 
1H), 4.62 (br d, J = 5.1 Hz, 2H), 4.46 (dd, J1 = 6.5 Hz, J2 = 3.0 Hz, 1H).  13C NMR (400 
MHz, CDCl3): δ 166.2, 165.8, 165.6, 165.4, 160.7, 133.7, 133.5, 133.4, 130.1, 129.91, 
129.86, 129.7, 129.0, 128.73, 128.66, 128.60, 128.55, 128.51, 93.3, 90.9, 70.9, 70.3, 68.8, 
62.6. 
Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-1,2:5,6-di-O-isopropylidene-α-D-
glucofuranose (70)75:  Trichloroacetimidate 69 (2.0 g, 2.7 mmol) and diacetone D-
glucose (650 mg, 2.5 mmol) were stirred under an atmosphere of nitrogen in anhydrous 
 76
dichloromethane (20 mL) with 3Ǻ molecular sieves for 1 hour.  The solution was cooled 
in an icebath for 30 minutes before BF3·OEt2 (2 mL) was added and stirred for 1 hour in 
the icebath followed by 1 hour at room temperature.  The solution was added to an ice-
cold saturated aqueous sodium bicarbonate solution (100 mL) with vigorous stirring and 
then extracted with ether (2 x 75 mL).  The organic layers were combined and dried over 
sodium sulfate.  The solvent was removed under reduced pressure and the residue was 
purified by flash column chromatography (CH2Cl2:THF 9:1 to 0:1) to give 70 as a white 
solid (1.1 g, 53 % yield).  1H NMR (400 MHz, CDCl3): δ 8.03 (d, J = 4.4 Hz, 2H), 7.91 
(t, J = 9.8 Hz, 4H), 7.80 (d, J = 4.4 Hz, 2H), 7.57 – 7.26 (m, 12H), 5.89 (m, 2H), 5.66 (t, 
J = 8.0 Hz, 1H), 5.51 (t, J = 8.8 Hz, 1 H), 4.90 (d, J = 3.8 Hz, 1H), 4.73 (dd, J1 = 6.2 Hz, 
J2 = 1.4 Hz, 1H),  4.42 (m, 2H), 4.28 (d, J = 1.4 Hz, 1H), 4.16 (m, 1H), 4.07 (m, 2H), 
4.01 (dd, J1 = 3.4 Hz, J2 = 1.2 Hz, 1H), 3.84 (q, J = 9.2 Hz, 1H), 1.36 (s, 6H), 1.26 (s, 
6H).  13C NMR (400 MHZ, CDCl3): δ 166.5, 166.0, 165.6, 165.4, 133.8, 133.7, 133.6, 
130.1, 130.0, 129.6, 129.2, 128.9, 128.7, 128.6, 112.0, 105.3, 102.0, 85.2, 79.7, 75.8, 
72.84, 72.77, 72.5, 72.2, 69.5, 69.4, 62.8, 27.0, 26.4.   
Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-D-glucopyranose (71):  Disaccharide 70 
(3.2 g, 3.8 mmol) was stirred at 40ºC in THF (10 mL) and a 1:1 mixture of trifluoroacetic 
acid and water (40 mL) for 24 hours.  The solution was then added slowly to water (400 
mL) with stirring.  The resulting solid was filtered and washed with water to give 71 as a 
white solid (2.5 g, 86 % yield).  1H NMR (400 MHz, CDCl3): δ 7.99 – 7.86 (m, 6H), 7.80 
(d, J = 3.8 Hz, 2H), 7.47 – 7.21 (m, 12H), 5.90 (t, J = 9.6 Hz, 1H), 5.71 (t, J = 9.6 Hz, 
1H), 5.52 (t, J = 9.2 Hz, 1H), 5.05 (d, J = 1.6 Hz, 1H), 4.94 (d, J = 4.0 Hz, 1H), 4.69 (t, J 
= 12.8 Hz, 1H), 4.41 (m, 1H), 4.14 (m, 2H), 3.94 (m, 1H), 3.80 (m, 1H), 3.69 (t, J = 9.6 
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Hz, 1H), 3.41 (m, 1H), 3.31 (m, 1H).  13C NMR (400 MHz, CDCl3): δ 166.6, 166.0, 
165.7, 165.3, 133.6, 133.5, 133.4, 130.0, 129.9, 129.5, 129.2, 129.2, 129.2, 129.0, 129.0, 
128.6, 128.5, 128.4, 128.4, 102.0, 101.9, 96.6, 92.5, 77.4, 76.4, 75.2, 74.7, 73.6, 73.1, 
72.3, 72.2, 72.1, 70.8, 70.6, 70.4, 70.1, 69.9, 69.7, 63.1 
Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-tetra-O-benzoyl-D-glucopyranose (72):  
Disaccharide 71 (2.5 g, 3.3 mmol) was refluxed in pyridine (50 mL) for 30 minutes.  The 
solution was added to benzoyl chloride (10 mL) that had been heated to 65°C.  After the 
mixture was cooled to room temperature, water (200 mL) was added.  The resulting syrup 
was separated from the aqueous layer and dissolved in CH2Cl2 (50 mL).  The solution 
was washed with water (3 x 50 mL), dried over sodium sulfate, and the solvent was 
removed under reduced pressure.  The residue was crystallized from CH2Cl2/hexanes to 
give 72 as a white solid (3.0 g, 78 % yield).  1H NMR of 72α and β (400 MHz, CDCl3): δ 
8.12 – 7.77 (m, 32H), 7.62 – 7.15 (m, 48H), 6.69 (d, J = 1.8 Hz, 1H), 6.19 (t, J = 10.0 Hz, 
1H), 6.14 (d, J = 4.2 Hz, 1H), 5.92 (m, 2H), 5.71 – 5.41 (m, 7H), 5.08 (d, J = 3.8 Hz, 
1H), 5.00 (d, J = 4.0 Hz, 1H), 4.58 (dd, J1 = 6.0 Hz, J2 = 1.6 Hz, 1H), 4.51 – 4.37 (m, 
5H), 4.23 (m, 1H), 4.18 – 3.99 (m, 5H), 3.94 (dd, J1 = 6.2 Hz, J2 = 3.0 Hz, 1H), 3.86 (dd, 
J1 = 6.4 Hz, J2 = 3.0 Hz, 1H).  13C NMR of 72α and β (400 MHz, CDCl3): δ 172.0, 166.3, 
166.0, 165.8, 165.4, 164.9, 134.0, 133.6, 133.5, 133.4, 133.3, 130.4, 130.22, 130.16, 
130.1, 130.0, 129.8, 129.5, 129.4, 129.0, 128.9, 128.8, 128.7, 128.6, 128.51, 128.48, 
128.4, 101.1, 100.5, 92.9, 90.1, 75.4, 73.2, 73.0, 72.9, 72.4, 72.1, 71.9, 71.0, 70.6, 70.4, 
69.9, 69.4, 69.1, 67.5, 67.1, 63.2. 
Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-2,4,6-tri-O-benzoyl-D-glucopyranose 
(73):  Disaccharide 72 (3.4 g, 2.9 mmol) was stirred with 2-aminoethanol (500 mg, 8.2 
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mmol) and DMSO (0.5 mL) in ethyl acetate (50 mL) for 24 hours at room temperature.  
The mixture was washed with water (3 x 50 mL), dried over sodium sulfate, and 
concentrated.  The resulting syrup was purified by flash column chromatography (CH2Cl2 
followed by Et2O) to give 73 as a white solid (1.2 g, 40 % yield).  1H NMR of 73α (400 
MHz, CDCl3):  δ 8.08 – 7.77 (m, 14 H), 7.53 – 7.26 (m, 21 H), 6.11 (t, J = 10.0 Hz, 1H), 
5.90 (t, J = 9.6 Hz, 1H), 5.69 (t, J = 9.6 Hz, 1H), 5.49 (t, J = 10.0 Hz, 1H), 5.39 (d, J = 
1.8 Hz, 1H), 5.28 (t, J = 10.4 Hz, 1H), 5.10 (dd, J1 = 5.2 Hz, J2 = 1.8 Hz, 1H), 4.95 (d, J 
= 3.8 Hz, 1H), 4.71 (dd, J1 = 6.2 Hz, J2 = 1.4 Hz, 1H), 4.62 (m, 1H), 4.49 (m, 1H), 4.39 
(dd, J1 = 6.0 Hz, J2 = 2.2 Hz, 1H), 4.13 (m, 2H).  13C NMR of 73α  (400 MHz, CDCl3): δ 
166.5, 166.0, 165.9, 165.7, 165.4, 138.9, 133.7, 133.6, 133.5, 133.4, 133.3, 130.4, 130.1, 
130.1, 130.0, 130.0, 130.0, 129.8, 129.7, 129.6, 129.4, 129.3, 129.0, 128.8, 128.7, 128.6, 
128.5, 128.4, 102.5, 90.4, 77.4, 72.8, 72.6, 72.4, 72.3, 70.2, 69.9, 69.5, 69.0, 63.0. 
Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-tri-O-benzoyl-β-D-glucopyranosyl-
(1→3)-D-glucopyranose (76):  Disaccharide 73 (1.2 g, 1.2 mmol), potassium carbonate 
(0.42 g, 3.0 mmol), and trichloroacetonitrile (4 mL) were stirred 48 hours in CH2Cl2 (20 
mL) at room temperature.  The resulting suspension was filtered through silica gel using 
a 1:1 mixture of CH2Cl2 and Et2O (150 mL).  The filtrate was concentrated to give O-
(Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-tri-O-benzoyl-α-D-glucopyranosyl)-
trichloroacetimdate (74) as a pale yellow solid (1.3 g, 94 % yield) which was used 
immediately in the next reaction without further purification.  1H NMR of 74 (300 MHz, 
CDCl3): 8.36 (s, 1H), 7.98 – 7.73 (m, 14H), 7.51 – 7.26 (m, 21H), 6.64 (d, J = 2.0 Hz, 
1H), 6.14 (t, J = 9.8 Hz, 1H), 5.88 (t, J = 10.1 Hz, 1H), 5.63 – 5.32 (m, 4H), 4.98 (d, J = 
4.1 Hz, 1H), 4.40 – 4.61 (m, 3H), 4.13 (m, 2H), 3.84 (m, 1H).  Trichloroacetimidate 74 
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(0.66 g, 0.54 mmol) and 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (0.12 g, 0.45 
mmol) were stirred under an atmosphere of nitrogen in CH2Cl2 (20 mL) with 3Ǻ 
molecular sieves for 1 hour.  The solution was cooled in an icebath for 30 minutes before 
BF3·OEt2 (1 mL) was added and stirred for 1 hour in the icebath followed by 1 hour at 
room temperature.  The solution was added to ice-cold saturated aqueous sodium 
bicarbonate solution (50 mL) with vigorous stirring and then extracted with ether (3 x 50 
mL).  The organic layers were combined and dried over sodium sulfate.  The solvent was 
removed under reduced pressure and the residue was purified by flash column 
chromatography (CH2Cl2: THF 9:1 to 0:1) to give tetra-O-benzoyl-β-D-glucopyranosyl-
(1→3)-tri-O-benzoyl-β-D-glucopyranosyl-(1→3)-1,2:5,6-di-O-isopropylidene-α-D-
glucofuranose (75) as a white solid (0.21 g, 36 % yield) which was used immediately in 
the next reaction.  1H NMR of 75 (400 MHz, CDCl3): δ 8.04 (d, J = 4.5 Hz, 2H), 7.93 (d, 
J = 4.3 Hz, 2H), 7.88 – 7.71 (m, 8H), 7.53 – 7.19 (m, 21 H), 5.95 (d, J = 3.2 Hz, 1H), 
5.87 (t, J = 9.6 Hz, 1H), 5.78 (t, J = 9.5 Hz, 1H), 5.63 (t, J = 9.7 Hz, 1H), 5.52 (dd, J1 = 
4.9 Hz, J2 = 4.0 Hz, 1H), 5.36 (dd, J1 = 4.8 Hz, J2 = 4.0 Hz, 1H), 5.26 (t, J = 9.4 Hz, 1H), 
4.99 (d, J = 3.8 Hz, 1H), 4.67 (d, J = 3.9 Hz, 1H), 4.64 (dd, J1 = 6.1 Hz, J2 = 1.2 Hz, 1H), 
4.49 (d, J = 1.6 Hz, 1H), 4.44 (dd, J1 = 6.1 Hz, J2 = 2.6 Hz, 1H), 4.33 (br s, 1H), 4.13 (m, 
1H), 4.12 (m, 3H), 3.92 (m, 2H), 3.83 (m, 2H), 1.39 (s, 6H), 1.24 (s, 6H).  Trisaccharide 
75 (21 mg, 0.16 mmol) was stirred in THF (2 mL) and a 1:1 mixture of water and 
trifluoroacetic acid (10 mL) at 40°C for 24 hours.  The solution was cooled and added to 
water (100 mL).  Once the resulting oil solidified, it was filtered and washed with water 
to give 76 as a white solid (130 mg, 67 % yield).  1H NMR of 76 (400 MHz, CDCl3): δ 
8.04 (d, J = 3.6 Hz, 2H), 7.92 – 7.74 (m, 12H), 7.52 – 7.23 (m, 21H), 5.92 (t, J = 9.6 Hz, 
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1H), 5.78 (t, J = 9.6 Hz, 1H), 5.66 (t, J = 9.6 Hz, 1H), 5.53 (dd, J1 = 4.9 Hz, J2 = 4.2 Hz, 
1H), 5.39 (m, 2H), 5.28 (m, 2H), 4.65 (d, J = 4.0 Hz, 1H), 4.64 (d, J = 4.8 Hz, 1H), 4.47 
(dd, J1 = 6.1 Hz, J2 = 2.4 Hz, 1H), 4.17 (m, 1H), 4.04 – 3.92 (m, 4H),  3.84 – 3.80 (m, 
3H), 3.63 – 3.56 (m, 2H).  13C NMR of 76 (400 MHz, CDCl3): δ 166.8, 166.5, 165.9, 
165.7, 165.5, 165.4, 133.8, 133.7, 133.5, 130.1, 130.0, 129.9, 129.7, 129.4, 128.9, 128.7, 
128.6, 128.5, 101.6, 101.2, 92.9, 77.4, 75.1, 74.7, 73.4, 72.6, 72.5, 72.0, 71.9, 70.4, 70.2, 
69.9, 69.8, 69.1, 67.9, 63.2. 
Tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-tri-O-benzoyl-β-D-glucopyranosyl-
(1→3)-tetra-O-benzoyl-D-glucopyranose (77):  Trisaccharide 76 (130 mg, 0.11 mmol) 
was refluxed in pyridine (5 mL) for 30 minutes.  The resulting solution was added to 
benzoyl chloride (2 mL) that had previously been heated to 65°C.  The mixture was 
cooled to room temperature and then water (50 mL) was added.  The resulting oil was 
separated from the aqueous layer and dissolved in CH2Cl2 (50 mL).  The solution was 
washed with water (3 x 50 mL), dried over sodium sulfate and concentrated.  The residue 
was purified by flash column chromatography (5:1 CH2Cl2:Et2O) to give 77 as a white 
solid (86 mg, 49 % yield).  1H NMR (400 MHz, CDCl3): 8.08 – 7.70 (m, 22H), 7.54 – 
7.15 (m, 33H), 6.20 (t, J = 10.0 Hz, 1H), 6.15 (t, J = 10.0 Hz, 1H), 5.96 (d, J = 4.2 Hz, 
1H), 5.77 (t, J = 11.2 Hz, 1H), 5.77  (m, 1H), 5.64 (t, J = 9.6 Hz, 1H), 5.61 (t, J = 9.6 Hz, 
1H), 5.47 (m, 1H), 5.22 (d, J = 4.0 Hz, 1H), 5.19 (d, J = 3.8 Hz, 1H), 5.04 (m, 1H), 4.90 
(t, J = 9.2 Hz, 1H), 4.66 – 4.57 (m, 2H), 4.48 – 4.41 (m, 2H), 4.26 (dt, J1 = 5.0 Hz, J2 = 
4.0 Hz, 1H), 4.03 – 3.76 (m, 3H), 3.46 (m, 1H).  13C NMR of 77α (400 MHz, CDCl3): δ 
166.4, 166.1, 166.0, 166.0, 165.8, 165.6, 165.5, 165.4, 165.2, 165.0, 164.7, 134.0, 133.9, 
133.7, 133.5, 133.4, 133.3, 133.2, 133.1, 130.5, 130.3, 130.1, 130.0, 129.9, 129.6, 129.5, 
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129.4, 129.3, 129.2, 129.1, 129.1, 128.9, 128.8, 128.8, 128.7, 128.6, 128.6, 128.5, 128.5, 
128.4, 101.6, 93.1, 90.3, 74.8, 74.6, 73.9, 73.0, 71.9, 71.7, 71.2, 70.8, 70.6, 70.4, 70.3, 
69.9, 69.8, 68.6, 68.1.  ESI m/z = 1671.7 (M+Na)+.   
Penta-O-acetyl-D-glucopyranose (78)80:  D-glucose (20 g, 110 mmol) was refluxed in 
pyridine (150 mL) for 1 hour.  Acetic anhydride (100 mL) was added and the mixture 
was refluxed an additional 2 hours.  The resulting solution was cooled to room 
temperature, poured over ice (300 mL) and stirred until the product solidified, about 2 
hours.  The solid was filtered, washed with water, and recrystallized from ethyl 
acetate/hexanes to give 78 as a white solid (36 g, 83 % yield).  78β:  D-glucose (5.0 g, 28 
mmol), sodium acetate (4.0 g, 50 mmol), and acetic anhydride (30 mL) were stirred at 
100°C for 3 hours.  The mixture was cooled to room temperature, poured over ice (150 
mL) and stirred for 2 hours.  The resulting white solid was filtered and washed with water 
and recrystallized from methanol to give 78β as a white solid (3.7 g, 38 % yield).  1H 
NMR of 78β (400 MHZ, CDCl3): δ 5.72 (d, J = 4.0 Hz, 1H), 5.26 (t, J = 9.2 Hz, 1H), 
5.14 (t, J = 8.8 Hz, 1H), 5.13 (t, J = 10.0 Hz, 1H), 4.30 (dd, J1 = 6.2 Hz, J2 = 2.2 Hz, 1H), 
4.12 (dd, J1 = 6.3 Hz, J2 = 1.0 Hz, 1H), 3.84 (m, 1H), 2.12 (s, 3H), 2.09 (s, 3H), 2.04 (s, 
6H), 2.01 (s, 3H).  13C NMR of 78β (400 MHz, CDCl3): δ 170.7, 170.3, 169.8, 169.5, 
168.9, 89.1, 69.9, 69.2, 67.9, 61.5, 20.9, 20.8, 20.7, 20.6, 20.5. 
2,3,4,6-tetra-O-acetyl-D-glucopyranose (79)76: D-glucose pentaacetate 78 (10 g, 26 
mmol) and 2-aminoethanol (3.9 g, 64 mmol) were dissolved in ethyl acetate (250 mL) 
and DMSO (2.5 mL) and stirred at room temperature overnight.  The mixture was 
washed with water (3 x 150 mL), dried over sodium sulfate and concentrated to give 79 
as colorless syrup (6.2 g, 70% yield).  This product was used immediately in the further 
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reactions without further purification.  1H NMR of 79α (300 MHz, CDCl3): δ 5.51 (t, J = 
9.9 Hz, 1H), 5.45 (d, J = 1.5 Hz, 1H), 5.06 (t, J = 9.9 Hz, 1H), 4.89 (dd, J1 = 5.03 Hz, J2 
= 1.8 Hz, 1H), 4.26 – 4.06 (m, 3H), 2.07 (s, 3H), 2.06, (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H).  
13C NMR of 79α (400 MHz, CDCl3): δ 171.2, 170.5, 170.4, 169.9, 95.3, 73.0, 72.5, 71.9, 
68.4, 68.2, 20.8, 20.7, 20.6, 20.6.  13C NMR of 79β (400 MHz, CDCl3): δ 171.2, 170.5, 
170.4, 169.9, 90.0, 71.2, 70.0, 68.6, 67.0, 62.0, 20.8, 20.7, 20.6, 20.6. 
1,3,4,6-Tetra-O-acetyl-α-D-glucopyranose (81)82: Tetraacetate 79 (3.5 g, 10 mmol) was 
stirred in 80 mL chloroform with 3 Å molecular sieves under an atmosphere of nitrogen 
for 1 hour.  (1-Chloro-2-methylpropenyl)-dimethylamine (2.0 mL, 11 mmol) was added 
and the mixture was stirred at room temperature overnight.  The mixture was filtered and 
the solvent was removed under reduced pressure to give tetra-O-acetyl-D-glucopyranosyl 
chloride 80 as a colorless syrup which was used immediately in the following reaction 
without further purification.  1H NMR of 80α (300 MHz, CDCl3): δ 5.26 (br d, J = 4.1 
Hz, 1H), 5.18 – 5.03 (m, 2H), 4.22 (dd, J1 = 6.3 Hz, J2 = 2.1 Hz, 1H), 4.13 (d, J = 0.8 Hz, 
1H), 4.05 (m, 1H), 3.78 (m, 1H), 2.05 (s, 3H), 2.03 (s, 3H), 1.98 (s, 3H), 1.96 (s, 3H).  
Glucosyl chloride 80 was dissolved in acetone (50 mL).  DMF (2 mL) and water (5 mL) 
were added and the solution was stirred 5 hours at room temperature.  Pyridine (2 mL) 
was added and the solvents were removed under reduced pressure.  The resulting syrup 
was dissolved in ethyl acetate (100 mL), washed with water (2 x 100 mL), dried over 
sodium sulfate and concentrated.  The product was crystallized from ether/hexanes to 
give 59 as colorless needles (0.96 g, 27 % yield in 2 steps from 79).  1H NMR (300 MHz, 
CDCl3): δ 6.22 (d, J = 1.5 Hz, 1H), 5.25 (t, J = 7.2 Hz, 1H), 5.09 (t, J = 7.2 Hz, 1H), 4.26 
(dd, J1 = 4.8 Hz, J2 = 1.7 Hz, 1H), 4.05 – 3.99 (m, 2H), 3.88, (dd, J1 = 3.9 Hz, J2 = 1.5 
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Hz, 1H), 2.18 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H).  13C NMR (300 MHz, 
CDCl3): δ 171.7, 170.9, 169.7, 169.4, 91.5, 73.3, 70.0, 69.8, 67.6, 61.8, 21.2, 21.0, 20.9, 
20.8. 
Isopropyl tetra-O-acetyl-1-thio-β-D-glucopyranoside (92):  Penta-O-acetyl-β-D-
glucopyranose 78β (3.7 g, 9.4 mmol) and propane-2-thiol (1.0 mL, 13 mmol) were stirred 
at room temperature in CH2Cl2 with 3 Å molecular sieves for 30 minutes under an 
atmosphere of nitrogen.  BF3·OEt2 (3.5 mL) was added and the mixture was stirred an 
additional 2 hours.  The molecular sieves were filtered and the filtrate was added to 5 % 
NaHCO3 (50 mL) with vigorous stirring.  The organic layer was separated, washed with 5 
% NaHCO3 (3 x 50 mL), and dried over sodium sulfate.  The solvent was removed under 
reduced pressure and the resulting solid was used immediately in the next reaction 
without further purification.  1H NMR (400 MHz, CDCl3): δ 5.11 (t, J = 9.6 Hz, 1H), 
4.94 (t, J = 9.6 Hz, 1H), 4.86 (t, J = 9.6 Hz, 1H), 4.49 (d, J = 5.2 Hz, 1H), 4.11 (dd, J1 = 
6.2 Hz, J2 = 2.8 Hz, 1H), 4.00 (dd, J1 = 6.0 Hz, J2 = 1.2 Hz, 1H), 3.61 (m, 1H), 3.05 (m, 
1H), 1.94 (s, 3H), 1.92 (s, 3H), 1.90 (s, 3H), 1.88 (s, 3H), 1.19 (d, J = 2.2 Hz, 3H), 1.17 
(d, J = 2.2 Hz, 3H).  13C NMR (400 MHz, CDCl3): δ 170.6, 170.2, 169.4, 169.3, 83.3, 
75.6, 73.9, 70.1, 68.4, 62.2, 35.6, 24.0, 23.7, 20.7, 20.7, 20.5. 
Isopropyl 1-thio-β-D-glucopyranoside (93): Thioglucopyranoside 92 was dissolved in 
2:1 MeOH:CH2Cl2 (45 mL).  Sodium hydroxide (1N) was added to a pH ~ 9-10.  The 
solution was stirred at room temperature 6 hours, neutralized with acidic Dowex resin, 
and filtered.  The solvents were removed under reduced pressure and the resulting solid 
was co-evaporated with toluene (3 x 10 mL) and used immediately in the following 
reaction without further purification.  1H NMR (300 MHz, DMSO- D6): δ 4.31 (d, J = 4.8 
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Hz, 1H), 3.65 (dd, J1 = 5.9 Hz, J2 = 0.6 Hz, 1H), 3.40 (dd, J1 = 5.9 Hz, J2 = 2.9 Hz, 1H), 
3.18 – 2.93 (m, 5H), 1.22 (dd, J1 = 3.4 Hz, J2 = 2.1 Hz, 6H).  13C NMR (400 MHz, 
DMSO-D6): δ 84.5, 80.9, 78.3, 73.3, 70.1, 61.3, 33.4, 23.9, 23.8. 
Isopropyl (R)-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (84)86: 
Thioglucopyranoside 93 and dimethoxymethylbenzene (1.7 g, 11 mmol) were dissolved 
in DMF (15 mL).  The solution was cooled to 0°C and CSA was added to a pH ~ 2-3.  
After the mixture was stirred at room temperature overnight, it was neutralized with 
triethylamine.  Ethyl acetate (100 mL) was added and the resulting solution was washed 
with brine (2 x 100 mL), dried over sodium sulfate.  The solvents were removed under 
reduced pressure and the product was purified by flash column chromatography (1:1 
ethyl acetate: petroleum ether) to give 84 as a white solid (1.6 g, 51 % yield in 3 steps 
from 78β).  1H NMR (300 MHz, CDCl3): δ 7.55 – 7.36 (m, 5H), 5.55 (s, 2H), 4.54 (d, J = 
5.0 Hz, 1H), 4.35 (dd, J1 = 5.2 Hz, J2 = 2.3 Hz, 1H), 3.88 – 3.75 (m, 2H), 3.62 – 3.45 (m, 
3H), 3.24 (m, 1H), 1.36 (d, J = 3.3 Hz, 6H).  13C NMR (400 MHz, CDCl3): δ 129.4, 
128.5, 126.6, 126.5, 102.1, 86.5, 81.2, 72.3, 72.3, 68.9, 63.6, 36.5, 24.4, 23.8. 
Isopropyl tetra-O-benzoyl-β-D-glucopyranosyl-(1→3)-[tetra-O-benzoyl-β-D-
glucopyranosyl-(1→2)]-(R)-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (94):  
Trichloroacetimidate donor 69 (3.7 g, 5.0 mmol) and thioglucopyranoside 84 (1.5 g, 4.5 
mmol) were co-evaporated with toluene (3 x 10 mL), dried under reduced pressure 
overnight, and then stirred under an atmosphere of nitrogen in anhydrous CH2Cl2 (50 
mL), with 3Å molecular sieves for 1 hour.  The mixture was cooled to 0°C before 
TMSOTf (91 µL, 0.5 mmol) was added.  The reaction was stirred at 0°C for 5 hours, 
neutralized with triethylamine (0.3 mL), and filtered.  The solvents were removed under 
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reduced pressure and the product was purified by gravity column chromatography (2:3 
ethyl acetate: petroleum ether) to give isopropyl tetra-O-benzoyl-β-D-glucopyranosyl-
(1→3)-(R)-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (85) which was used 
immediately in the following reaction.  1H NMR of 85 (400 MHz, CDCl3): δ 8.14 – 7.82 
(m, 10H), 7.23 – 7.57 (m, 15 H), 5.92 (t, J = 9.2 Hz, 1H), 5.71 (t, J = 9.2 Hz, 1H), 5.57 (s, 
2H), 5.56 (dd, J1 = 3.6 Hz, J2 = 1.0 Hz, 1H), 5.22 (d, J = 4.0 Hz, 1H), 4.49 (dd, J1 = 5.9 
Hz, J2 = 1.8 Hz, 1H), 4.44 (d, J = 5.0 Hz, 1H), 4.33 (t, J = 12.0 Hz, 1H), 4.32 (t, J = 12.4 
Hz, 1H), 3.94 (m, 1H), 3.90 (t, J = 8.4 Hz, 1H), 3.77 (t, J = 10.8 Hz, 1H), 3.71, (t, J = 9.6 
Hz, 1H), 3.49 – 3.44 (m, 2H), 3.14 (m, 1H), 1.24 (d, J = 2.9 Hz, 6H).  Disaccharide 85 
and trichloroacetimidate donor 69 (3.0 g, 4.0 mmol) were co-evaporated with toluene (3 x 
10 mL), dried under reduced pressure overnight, and then stirred under an atmosphere of 
nitrogen in anhydrous CH2Cl2 (50 mL), with 3Å molecular sieves for 1 hour.  The 
mixture was cooled to 0°C before TMSOTf (91 µL, 0.5 mmol) was added.  The reaction 
was stirred at 0°C for 3 hours, neutralized with triethylamine (0.5 mL), and filtered.  The 
solvents were removed under reduced pressure and the product was purified by gravity 
column chromatography (2:3 ethyl acetate: petroleum ether) and then recrystallized from 
methanol to give 94 (1.6 g, 23 % yield in 2 steps from 84).  1H NMR (400 MHz, CDCl3): 
δ 8.29 – 7.21 (m, 45H), 5.83 (t, J = 9.2 Hz, 1H), 5.79 (t, J = 9.6 Hz, 1H), 5.61 – 5.52 (m, 
3H), 5.51 (s, 2H), 5.43 (t, J = 10.0 Hz, 1H), 4.97 (d, J = 3.8 Hz, 1H), 4.80 (d, J = 4.2 Hz, 
1H), 4.49 (d, J = 4.8 Hz, 1H), 4.37 (dd, J1 = 5.9 Hz, J2 = 1.6 Hz, 1H), 4.28 – 4.18 (m, 
4H), 4.00 (t, J = 8.8 Hz, 1H), 3.90 (t, J = 9.6 Hz, 1H), 3.69 (t, J = 10.8 Hz, 1H), 3.62 (t, J 
= 9.2 Hz, 1H), 3.30 (m, 1H), 3.07 (m, 1H), 2.79 (m, 1H), 2.67 (m, 1H), 1.22 (d, J = 3.2 
Hz, 3H), 1.09, (d, J = 3.4 Hz, 3H).  13C NMR (400 MHz, CDCl3): δ 166.5, 166.1, 166.0, 
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165.5, 165.4, 165.3, 163.9, 133.8, 133.7, 133.6, 133.5, 133.3, 130.3, 130.2, 130.1, 130.0, 
129.9, 129.8, 129.7, 129.7, 129.6, 129.6, 129.5, 129.4, 129.4, 129.3, 129.2, 129.1, 129.0, 
128.9, 128.9, 128.7, 128.6, 128.5, 128.5, 128.3, 128.3, 126.2, 101.4, 100.0, 99.6, 96.1, 
92.1, 84.0, 80.9, 78.6, 77.4, 76.7, 73.1, 72.5, 71.5, 71.3, 70.8, 69.2, 68.7, 63.6, 62.2, 34.3, 
23.8, 23.6. 
1,2,3,6-Tetra-O-benzoyl-α-D-galactopyranose (90)90:  Under an atmosphere of 
nitrogen, benzoyl chloride (16 g, 90 mmol) in pyridine (5 mL) was added over 30 
minutes to a suspension of D-galactose (5.0 g, 28 mmol) in pyridine (100 mL) at 0°C.  
The mixture was stirred 1 hour before ice (200 mL) was added and extracted with CH2Cl2 
(3 x 100 mL).  The organic layers were combined and washed with 2M H2SO4 (100 mL), 
followed by saturated aqueous NaHCO3 (100 mL), and finally water (100 mL), and dried 
over sodium sulfate.  The solvents were removed under reduced pressure and the residue 
was purified by gravity column chromatography (4:1 toluene: ethyl acetate) to give 90 as 
a colorless syrup (11 g, 65 % yield).  1H NMR (300 MHz, CDCl3): δ 8.09 – 7.25 (m, 
20H), 6.81 (d, J = 2.0 Hz, 1H), 6.05 (dd, J1 = 5.4 Hz, J2 = 1.8 Hz, 1H), 5.86 (dd, J1 = 5.3 
Hz, J2 = 1.5 Hz, 1H), 4.76 (dd, J1 = 5.4 Hz, J2 = 3.3 Hz, 1H), 4.55 – 4.44 (m, 2H), 4.49 
(br s, 1H), 2.79 (d, J = 2.0 Hz, 1H).  13C NMR (400 MHz, CDCl3): δ 166.8, 166.2, 165.8, 
164.8, 133.9, 133.7, 133.5, 130.1, 130.0, 130.0, 129.9, 129.8, 129.4, 129.3, 129.1, 129.0, 
128.8, 128.8, 128.6, 128.5, 128.5, 128.4, 128.4, 91.0, 71.1, 70.9, 67.7, 67.4, 63.0. 
Tetra-O-acetyl-α-D-glucopyranosyl-(1→4)-tetra-O-benzoyl-α-D-galactopyranose 
(96):  Isopropyl thioglucopyranoside donor 92 (1.0 g, 2.5 mmol) and galactopyranosyl 
acceptor 90 were co-evaporated with toluene (3 x 10 mL), dried under reduced pressure 
overnight, and then stirred under an atmosphere of nitrogen in anhydrous CH2Cl2 (50 
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mL), with 3Å molecular sieves for 1 hour.  The mixture was cooled to -42°C and N-
iodosuccinimide (620 mg, 2.7 mmol) and TMSOTf (55 µL, 0.30 mmol).  The reaction 
was stirred at -42°C for 2 hours, neutralized with triethylamine, and filtered.  The 
solvents were removed under reduced pressure and the resulting syrup was purified by 
gravity column chromatography (3:2 petroleum ether: ethyl acetate) to give 96 as a white 
solid (1.7 g, 74 % yield).  1H NMR (400 MHz, CDCl3): δ 8.17 – 7.23 (m, 20H), 6.80 (d, J 
= 2.0 Hz, 1H), 6.05 (dd, J1 = 5.4 Hz, J2 = 2.0 Hz, 1H), 5.74 (d, J = 2.4 Hz, 1H), 5.62 (dd, 
J1 = 5.4 Hz, J2 = 1.6 Hz, 1H), 4.92 (t, J = 3.6 Hz, 1H), 4.77, (dd, J1 = 4.4 Hz, J2 = 2.2 Hz, 
1H), 4.70 (br d, J = 1.4 Hz, 1H), 4.62 – 4.54 (m, 2H), 4.46 – 4.38 (m, 2H), 4.10 (m, 1H), 
3.96 (dd, J1 = 6.2 Hz, J2 = 1.2 Hz, 1H), 3.74 (m, 1H), 2.08 (s, 3H), 2.00 (s, 3H), 1.99 (s, 
3H), 1.97 (s, 3H).   
Tetra-O-acetyl-α-D-glucopyranosyl trichloroacetimidate (97)77:  2,3,4,6-Tetra-O-
acetyl –D-glucopyranose 79 (2.0 g, 3.3 mmol), K2CO3 (1.1 g, 8.2 mmol), and 
trichloroacetonitrile (5 mL) were stirred at room temperature in dichloromethane (20 mL) 
for 48 hours.  The resulting suspension was filtered through silica gel using a 1:1 mixture 
of CH2Cl2 and Et2O (150 mL).  The filtrate was concentrated to give 97 as a pale yellow 
solid (2.0 g, 83 % yield).  1H NMR (400 MHz, CDCl3): δ 8.67 (s, 1H), 6.52 (d, J = 1.8 
Hz, 1H), 5.53 (t, J = 9.6 Hz, 1H), 5.15 (t, J = 10.0 Hz, 1H), 5.10 (dd, J1 = 6.8 Hz, J2 = 2.0 
Hz, 1H), 4.24 (dd, J1 = 6.2 Hz, J2 = 2.0 Hz, 1H), 4.18 (m, 1H), 4.10 (dd, J1 = 6.0 Hz, J2 = 
1.0 Hz, 1H), 2.05 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H).  13C NMR (400 MHz, 
CDCl3): δ 170.9, 170.3, 170.2, 169.8, 161.0, 93.0, 70.2, 70.0, 69.9, 67.9, 61.5, 20.8, 20.8, 
20.6. 
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Tetra-O-acetyl-β-D-glucopyranosyl-(1→4)-tetra-O-benzoyl-α-D-galactopyranose 
(98): Trichloroacetimidate glucosyl donor 97 (900 mg, 1.8 mmol) and galactopyranosyl 
acceptor 90 (1.0 g, 1.8 mmol) were co-evaporated with toluene (3 x 10 mL), dried under 
reduced pressure overnight, and then stirred under an atmosphere of nitrogen in 
anhydrous CH2Cl2 (50 mL), with 3Å molecular sieves for 1 hour.  The mixture was 
cooled to 0°C before TMSOTf (41 µL, 0.18 mmol) was added.  The reaction was stirred 
for 3 hours at 0°C, quenched with triethylamine, and filtered.  The solvents were removed 
under reduced pressure and the resulting syrup was purified by gravity column 
chromatography (2:3 ethyl acetate: petroleum ether) to give 98 as a colorless syrup (620 
mg, 37 % yield).  1H NMR (400 MHz, CDCl3): δ 8.11 (d, J = 3.6 Hz, 2H), 8.06 (d, J = 
3.4 Hz, 2H), 7.95 (d, J = 3.6 Hz, 2H), 7.59 (d, J = 3.6 Hz, 2H), 7.51 – 7.22 (m, 12 H), 
6.72 (d, J = 2.0 Hz, 1H), 5.98 (dd, J1 = 5.4 Hz, J2 = 1.2 Hz, 1H), 5.86 (dd, J1 = 5.2 Hz, J2 
= 1.8 Hz, 1H), 5.19 (t, J = 8.0 Hz, 1H), 5.15 – 5.04 (m, 2H), 4.76 (d, J = 3.8 Hz, 1H), 
4.67 (dd, J1 = 5.8 Hz, J2 = 2.8 Hz, 1H), 4.58 (br s, 1H), 4.38 (dd, J1 = 5.8 Hz, J2 = 3.0 Hz, 
1H), 4.28 (m, 1H), 4.00 (dd, J1 = 4.0 Hz, J2 = 2.2 Hz, 1H), 3.78 (dd, J1 = 6.0 Hz, J2 = 1.2 
Hz, 1H), 3.46 (m, 1H).  13C NMR (400 MHz, CDCl3): δ 170.8, 170.5, 169.7, 169.3, 
166.0, 165.9, 165.3, 164.6, 134.2, 133.9, 133.5, 133.3, 130.0, 129.9, 129.8, 129.7, 129.3, 
128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 100.8, 90.9, 74.0, 72.7, 71.9, 71.3, 70.8, 70.5, 
68.1, 67.3, 63.4, 61.4, 20.8, 20.7, 20.6, 20.6. 
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APPENDIX 
 
1H and 13C NMR Spectra 
 
 
Figure 11. 1H NMR of 17 (400 MHz, CDCl3). 
 
 
 
 
Figure 12.  13C NMR of 17 (400 MHz, CDCl3). 
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Figure 13.  1H NMR of 26α (400 MHz, CDCl3). 
 
 
 
 
 
Figure 14.  13C NMR of 26α (400 MHz, CDCl3). 
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Figure 15.  1H NMR of 26β (400 MHz, CDCl3). 
 
 
 
 
Figure 16.  1H NMR of 27 (400 MHz, CDCl3). 
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Figure 17.  13C NMR of 27 (400 MHz, CDCl3). 
 
 
 
 
 
Figure 18.  1H NMR of 28 (500 MHz, CDCl3). 
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Figure 19.  1H NMR of 29 (400 MHz, CDCl3). 
 
 
 
 
 
Figure 20.  1H NMR of 32 (400 MHz, CDCl3). 
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Figure 21.  13C NMR of 32(400 MHz, CDCl3). 
 
 
 
 
Figure 22.  1H NMR of 34 (400 MHz, CDCl3). 
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Figure 23.  13C NMR of 34 (400 MHz, CDCl3). 
 
 
 
 
Figure 24.  1H NMR of 35 (400 MHz, CDCl3). 
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Figure 25.  1H NMR of 41 (400 MHz, CDCl3). 
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Figure 26.  1H NMR of 42 (400 MHz, CDCl3). 
 
 
 
 
Figure 27.  13C NMR of 42 (400 MHz, CDCl3). 
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Figure 28.  1H NMR of 43 (400 MHz, CDCl3). 
 
 
 
 
Figure 29.  13C NMR of 43 (400 MHz, CDCl3). 
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Figure 30  1H NMR of 46 (400 MHz, CDCl3). 
 
 
 
 
Figure 31.  1H NMR of 47 (400 MHz, CDCl3). 
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Figure 32.  1H NMR of 49 (400 MHz, CDCl3). 
 
 
 
 
 
Figure 33.  1H NMR of 67 (400 MHz, CDCl3). 
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Figure 34.  13C NMR of 67 (400 MHz, CDCl3). 
 
 
 
 
 
Figure 35.  1H NMR of 68 (400 MHz, CDCl3). 
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Figure 36.  13C NMR of 68 (400 MHz, CDCl3). 
 
 
 
 
 
Figure 37.  1H NMR of 69 (400 MHz, CDCl3). 
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Figure 38.  13C NMR of 69 (400 MHz, CDCl3). 
 
 
 
 
Figure 39.  1H NMR of 70 (400 MHz, CDCl3). 
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Figure 40.  13C NMR of 70 (400 MHz, CDCl3). 
 
 
 
 
Figure 41.  1H NMR of 71 (400 MHz, CDCl3). 
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Figure 42.  13C NMR of 71 (400 MHz, CDCl3). 
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Figure 43.  1H NMR of 72 (400 MHz, CDCl3). 
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Figure 44.  13C NMR of 72 (400 MHz, CDCl3). 
 
 
 
 
 
Figure 45.  1H NMR of 75 (300 MHz, CDCl3). 
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Figure 46.  1H NMR of 76 (300 MHz, CDCl3). 
 
 
 
 
Figure 47.  13C NMR of 76 (400 MHz, CDCl3). 
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Figure 48.  1H NMR of 77 (400 MHz, CDCl3). 
 
 
 
 
Figure 49.  13C NMR of 77 (400 MHz, CDCl3). 
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Figure 50.  1H NMR of 78 (400 MHz, CDCl3). 
 
 
 
 
Figure 51.  13C NMR of 78 (400 MHz, CDCl3). 
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Figure 52.  1H NMR of 79 (400 MHz, CDCl3). 
 
 
 
 
Figure 53.  13C NMR of 79 (400 MHz, CDCl3). 
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Figure 54.  1H NMR of 81 (400 MHz, CDCl3). 
 
 
 
 
Figure 55.  13C NMR of 81 (400 MHz, CDCl3). 
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Figure 56.  1H NMR of 84 (400 MHz, CDCl3). 
 
 
 
 
Figure 57.  13C NMR of 84 (400 MHz, CDCl3). 
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Figure 58.  1H NMR of 85 (400 MHz, CDCl3). 
 
 
 
 
 
Figure 59.  1H NMR of 90 (400 MHz, CDCl3). 
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Figure 60.  13C NMR of 90 (400 MHz, CDCl3). 
 
 
 
 
 
Figure 61.  1H NMR of 92 (400 MHz, CDCl3). 
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Figure 62.  13C NMR of 92 (400 MHz, CDCl3). 
 
 
 
 
Figure 63.  1H NMR of 93 (400 MHz, CDCl3). 
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Figure 64.  13C NMR of 93 (400 MHz, CDCl3). 
 
 
 
 
Figure 65.  1H NMR of 94 (400 MHz, CDCl3). 
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Figure 66.  1H NMR of 96 (400 MHz, CDCl3). 
 
 
 
 
Figure 67.  1H NMR of 97 (400 MHz, CDCl3). 
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Figure 68.  1H NMR of 98 (400 MHz, CDCl3). 
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X-Ray Crystallography Data for 32 
 
 
Table 3.  Crystal data and structure refinement for 32. 
   
Empirical formula   C29H46O5  
Formula weight   474.66  
Temperature    150(2) K  
Wavelength    0.71073 Å  
Crystal system, space group  Monoclinic,  P21  
Unit cell dimensions   a =  8.247(2) Å   α = 90 deg.  
                                     b = 10.773(3) Å   β = 91.932(5) deg.  
                                     c = 14.884(4) Å   γ = 90 deg.  
Volume                              1321.5(6) Å3  
Z, Calculated density              2,  1.193 Mg/m3  
Absorption coefficient             0.079 mm-1  
F(000)                              520  
Crystal size                        0.60 x 0.20 x 0.03 mm  
Theta range for data collection    2.33 to 22.49 deg.  
Limiting indices                    -8 ≤ h ≤ 8, -11 ≤ k ≤ 11, -15 ≤ l ≤ 16  
Reflections collected / unique     9729 / 3357 [R(int) = 0.0569]  
Completeness to theta = 22.49      98.4 %  
Absorption correction              Empirical  
Max. and min. transmission         0.925116 and 0.747318  
Refinement method                  Full-matrix least-squares on F2  
Data / restraints / parameters     3357 / 338 / 329  
Goodness-of-fit on F2              1.043  
Final R indices [I>2σ(I)]          R1 = 0.0598, wR2 = 0.1653  
R indices (all data)               R1 = 0.0637, wR2 = 0.1698  
Extinction coefficient              0.005(3)  
Largest diff. peak and hole        0.335 and -0.309 e.Å-3  
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Table 4.  Atomic coordinates ( x104) and equivalent isotropic displacement parameters 
(Å2 x 103) for 32.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
         ________________________________________________________________  
   
                              x                 y                    z              U(eq)  
         ________________________________________________________________  
   
          C(1)          2453(5)          0(4)        12722(2)       26(1)  
          O(1)           182(4)       -1446(3)       14869(2)       41(1)  
          C(2)          1301(5)         -67(4)       13491(3)       30(1)  
          O(2)           336(3)       -1200(3)       13390(2)       31(1)  
          C(3)           164(5)        1037(4)       13526(3)       34(1)  
          O(3)          1157(4)        2078(3)       13795(2)       45(1)  
          C(4)         -666(5)        1265(4)       12630(3)       33(1)  
          C(5)           560(5)        1430(4)       11897(3)       24(1)  
          C(6)          -232(5)        1811(4)       10996(3)       32(1)  
          C(7)          1030(4)        2054(4)       10288(3)       28(1)  
          C(8)          2208(4)         982(3)       10197(3)       19(1)  
          C(9)          2987(4)         632(3)       11116(2)       17(1)  
          C(10)         1659(4)         275(3)       11799(2)       19(1)  
          C(11)         4339(4)        -332(4)       11051(2)       20(1)  
          C(12)         5597(4)         24(3)       10348(2)       20(1)  
          C(13)         4770(4)         250(3)        9429(2)         18(1)  
          C(14)         3513(4)        1296(3)        9533(3)         18(1)  
          C(15)         3024(4)        1651(4)        8581(3)         26(1)  
          O(16)         4471(3)         758(2)       7318(2)         22(1)  
          C(16)         4628(4)        1534(3)       8086(3)         22(1)  
          C(17)         5862(4)         855(3)        8723(3)         21(1)  
          C(18)         3974(5)        -945(3)        9066(3)         22(1)  
          C(19)          723(5)        -878(4)       11462(3)       29(1)  
          C(20)         6810(4)          36(4)        8089(3)         22(1)  
          C(21)         6072(4)         315(3)        7157(3)         22(1)  
          O(21)         6987(3)        1283(3)        6779(2)         27(1)  
          C(22)         5921(5)        -792(4)        6535(3)         32(1)  
          C(23)         5339(6)        -427(4)        5598(3)         38(1)  
          C(24)         6356(5)         643(4)        5249(3)         36(1)  
          C(25)         6360(5)        1670(4)        5920(3)         30(1)  
          C(26)         8645(5)         197(4)        8169(3)         29(1)  
          C(27)         5795(6)        1085(5)        4315(3)         47(1)  
          C(28)         -122(5)       -1796(4)       14118(3)       29(1)  
          C(29)        -1034(6)       -2962(5)       13886(3)       46(1)  
         
________________________________________________________________  
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Table 5.  Bond lengths [Å] and angles [deg] for 32. 
           _____________________________________________________________  
   
    C(1)-C(2)                      1.514(5)  
            C(1)-C(10)                     1.531(5)  
            O(1)-C(28)                     1.198(5)  
            C(2)-O(2)                      1.462(5)  
            C(2)-C(3)                      1.516(6)  
            O(2)-C(28)                     1.326(5)  
            C(3)-O(3)                      1.438(5)  
            C(3)-C(4)                      1.498(6)  
            C(4)-C(5)                      1.524(5)  
            C(5)-C(6)                      1.528(6)  
            C(5)-C(10)                     1.549(5)  
            C(6)-C(7)                      1.528(5)  
            C(7)-C(8)                      1.518(5)  
            C(8)-C(14)                     1.524(5)  
            C(8)-C(9)                      1.539(5)  
            C(9)-C(11)                     1.529(5)  
            C(9)-C(10)                     1.567(5)  
            C(10)-C(19)                    1.537(5)  
            C(11)-C(12)                    1.546(5)  
            C(12)-C(13)                    1.528(5)  
            C(13)-C(18)                    1.535(5)  
            C(13)-C(14)                    1.542(5)  
            C(13)-C(17)                    1.550(5)  
            C(14)-C(15)                    1.509(5)  
            C(15)-C(16)                    1.540(5)  
            O(16)-C(16)                    1.419(5)  
            O(16)-C(21)                    1.431(4)  
            C(16)-C(17)                    1.550(5)  
            C(17)-C(20)                    1.526(5)  
            C(20)-C(26)                    1.524(5)  
            C(20)-C(21)                    1.526(5)  
            C(21)-O(21)                    1.414(5)  
            C(21)-C(22)                    1.512(6)  
            O(21)-C(25)                    1.426(5)  
            C(22)-C(23)                    1.511(6)  
            C(23)-C(24)                    1.527(7)  
            C(24)-C(25)                    1.490(6)  
            C(24)-C(27)                    1.527(6)  
            C(28)-C(29)                    1.499(6) 
  
            C(2)-C(1)-C(10)              115.3(3)  
            O(2)-C(2)-C(1)               108.4(3)  
            O(2)-C(2)-C(3)               108.9(3)  
            C(1)-C(2)-C(3)               113.2(3)  
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            C(28)-O(2)-C(2)              119.3(3)  
            O(3)-C(3)-C(4)               111.1(3)  
            O(3)-C(3)-C(2)               105.9(3)  
            C(4)-C(3)-C(2)               111.3(3)  
            C(3)-C(4)-C(5)               111.3(3)  
            C(4)-C(5)-C(6)               112.7(3)  
            C(4)-C(5)-C(10)              112.2(3)  
            C(6)-C(5)-C(10)              111.6(3)  
            C(5)-C(6)-C(7)               111.7(3)  
            C(8)-C(7)-C(6)               112.6(3)  
            C(7)-C(8)-C(14)              110.9(3)  
            C(7)-C(8)-C(9)               110.9(3)  
            C(14)-C(8)-C(9)              110.4(3)  
            C(11)-C(9)-C(8)              113.2(3)  
            C(11)-C(9)-C(10)             113.7(3)  
            C(8)-C(9)-C(10)              110.9(3)  
            C(1)-C(10)-C(19)             109.4(3)  
            C(1)-C(10)-C(5)              107.8(3)  
            C(19)-C(10)-C(5)             113.0(3)  
            C(1)-C(10)-C(9)              110.0(3)  
            C(19)-C(10)-C(9)             109.9(3)  
            C(5)-C(10)-C(9)              106.7(3)  
            C(9)-C(11)-C(12)             112.4(3)  
            C(13)-C(12)-C(11)            110.9(3)  
            C(12)-C(13)-C(18)            110.7(3)  
            C(12)-C(13)-C(14)            107.9(3)  
            C(18)-C(13)-C(14)            111.5(3)  
            C(12)-C(13)-C(17)            115.0(3)  
            C(18)-C(13)-C(17)            111.4(3)  
            C(14)-C(13)-C(17)             99.7(3)  
            C(15)-C(14)-C(8)             119.6(3)  
            C(15)-C(14)-C(13)            104.5(3)  
            C(8)-C(14)-C(13)             113.2(3)  
            C(14)-C(15)-C(16)            102.8(3)  
            C(16)-O(16)-C(21)            105.8(3)  
            O(16)-C(16)-C(15)            112.1(3)  
            O(16)-C(16)-C(17)            104.7(3)  
            C(15)-C(16)-C(17)            107.6(3)  
            C(20)-C(17)-C(16)            103.6(3)  
            C(20)-C(17)-C(13)            119.8(3)  
            C(16)-C(17)-C(13)            103.2(3)  
            C(26)-C(20)-C(21)            114.4(3)  
            C(26)-C(20)-C(17)            114.5(3)  
            C(21)-C(20)-C(17)            104.5(3)  
            O(21)-C(21)-O(16)            109.2(3)  
            O(21)-C(21)-C(22)            111.8(3)  
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            O(16)-C(21)-C(22)            107.9(3)  
            O(21)-C(21)-C(20)            107.8(3)  
            O(16)-C(21)-C(20)            104.8(3)  
            C(22)-C(21)-C(20)            115.0(3)  
            C(21)-O(21)-C(25)            113.0(3)  
            C(23)-C(22)-C(21)            112.2(4)  
            C(22)-C(23)-C(24)            110.4(4)  
            C(25)-C(24)-C(23)            108.7(3)  
            C(25)-C(24)-C(27)            111.8(4)  
            C(23)-C(24)-C(27)            113.1(4)  
            O(21)-C(25)-C(24)            112.1(3)  
            O(1)-C(28)-O(2)              123.7(4)  
            O(1)-C(28)-C(29)             124.5(4)  
            O(2)-C(28)-C(29)             111.8(4)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
             
 
  
Table 6.  Anisotropic displacement parameters (Å2 x103) for 32.  The anisotropic 
displacement factor exponent takes the form: -2pi2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
 
_____________________________________________________________________  
   
 U11     U22          U33   U23       U13 U12  
     
_______________________________________________________________________  
   
    C(1)            28(2)        25(2)        25(2)         1(2)         7(2)        -1(2)  
    O(1)      46(2)        44(2)        34(2)         7(2)        13(1)      -7(2)  
    C(2)      26(2)        32(2)        32(2)         1(2)         4(2)        -6(2)  
    O(2)      31(2)        30(2)        32(2)         5(1)         6(1)        -8(1)  
    C(3)      34(2)        30(2)        38(2)        -3(2)        14(2)       -8(2)  
    O(3)      48(2)        37(2)        51(2)        16(2)        18(2)     -7(2)  
    C(4)      26(2)        28(2)        45(2)         5(2)        17(2)        4(2)  
    C(5)      20(2)        20(2)        34(2)         3(2)        10(2)        1(2)  
    C(6)      23(2)        33(2)        40(2)         7(2)        12(2)       11(2)  
    C(7)      22(2)        24(2)        37(2)         9(2)         5(2)        9(2)  
    C(8)      14(2)        15(2)        29(2)         3(2)         6(1)        -2(1)  
    C(9)      14(2)        13(2)        24(2)         1(2)         4(1)        -4(1)  
    C(10)     17(2)        14(2)        26(2)         0(2)         6(1)        -4(1)  
    C(11)     18(2)        22(2)        22(2)         3(2)         3(1)        1(2)  
    C(12)     19(2)        16(2)        25(2)        -1(2)         5(1)        3(2)  
    C(13)     16(2)        14(2)        23(2)         0(2)         2(1)      -3(1)  
    C(14)     17(2)        10(2)        26(2)         2(2)         4(1)      -2(2)  
    C(15)     22(2)        22(2)        35(2)         4(2)         7(2)        7(2)  
    O(16)     22(1)        19(1)        26(1)         0(1)         5(1)        1(1)  
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    C(16)     22(2)        14(2)        32(2)         1(2)         5(2)       -1(1)  
    C(17)     21(2)        13(2)        30(2)         0(2)         1(1)       -3(1)  
    C(18)     27(2)        15(2)        25(2)         1(2)         5(2)       -4(2)  
    C(19)     27(2)        19(2)        40(2)        -1(2)         4(2)      -10(2)  
    C(20)     25(2)        13(2)        29(2)         2(2)         8(2)       -4(2)  
    C(21)     19(2)        17(2)        30(2)         1(2)         7(1)        3(1)  
    O(21)     25(1)        28(1)        29(1)         5(1)         4(1)       -5(1)  
    C(22)     41(2)        25(2)        30(2)        -8(2)         7(2)        4(2)  
    C(23)     46(2)        35(2)        33(2)       -18(2)        4(2)        1(2)  
    C(24)     31(2)        50(3)        29(2)        -1(2)         6(2)       13(2)  
    C(25)     25(2)        34(2)        30(2)         9(2)         6(2)       -8(2)  
    C(26)     23(2)        32(2)        33(2)         0(2)         2(2)        7(2)  
    C(27)     43(3)        66(3)        31(2)         5(2)         4(2)        8(3)  
    C(28)     25(2)        32(2)        31(2)        11(2)         5(2)       -1(2)  
    C(29)     49(3)        48(3)        40(3)         8(2)        10(2)      -17(2)  
    
_______________________________________________________________________  
  
 
 
Table 7.  Hydrogen coordinates ( x104) and isotropic displacement parameters (Å2 x103) 
for 32.  
         ________________________________________________________________  
   
                          x              y              z            U(eq)  
         ________________________________________________________________  
   
          H(1A)         3037           -801          12687           31  
          H(1B)         3270            652          12860           31  
          H(2)          1950           -112          14070           36  
          H(3A)         -668            885          13987           41  
          H(3B)          260(70)       2650(70)      14180(40)       79(19)  
          H(4A)        -1346           2019          12664           39  
          H(4B)        -1386            555          12476           39  
          H(5)          1287           2130          12091           29  
          H(6A)         -884           2571          11080           38  
          H(6B)         -975           1144          10781           38  
          H(7A)          466           2203           9700           33  
          H(7B)         1645           2815          10452           33  
          H(8)          1630(50)        200(40)       9930(20)       19(9)  
          H(9)          3515           1405          11356           21  
          H(11A)        3855          -1145          10887           24  
          H(11B)        4898           -420          11647           24  
          H(12A)        6180            785          10547           24  
          H(12B)        6402           -652          10300           24  
          H(14)         4200(50)      2000(50)       9700(30)       36(12)  
          H(15A)        2602           2511           8551           31  
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          H(15B)        2191           1078          8325          31  
          H(16)         5046           2371           7919           27  
          H(17)         6607           1472           9022           25  
          H(18A)        3512           -795           8461           33  
          H(18B)        3110          -1199           9463           33  
          H(18C)        4791          -1603           9043           33  
          H(19A)        -154          -1061          11869           43  
          H(19B)        1464          -1588          11444           43  
          H(19C)         264          -719          10857           43  
          H(20)         6590(40)       -780(40)       8230(20)       16(10)  
          H(22A)        6991          -1204           6504           38  
          H(22B)        5151          -1395           6785           38  
          H(23A)        4186           -174           5607           46  
          H(23B)        5422          -1149           5191           46  
          H(24)         7497            339           5208           43  
          H(25A)        7026           2364           5701           36  
          H(25B)        5238           1978           5980           36  
          H(26A)        8927           1058           8029           44  
          H(26B)        9163           -362           7746           44  
          H(26C)        9025             -1           8784           44  
          H(27A)        6452           1798           4140           70  
          H(27B)        4652           1330           4324           70  
          H(27C)        5923            411           3881           70  
          H(29A)       -1210          -3438          14435           68  
          H(29B)        -405          -3461          13472           68  
          H(29C)       -2084          -2748          13598           68  
         ________________________________________________________________  
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